Crohn's and Colitis Foundation of America Annual Report

Voices
OF PROGRESS
ANNUAL REPORT

2008

Our Mission
To cure Crohn’s disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases.

Table of Contents
President’s Letter Research Report Research Awards Financial Statements Friends of CCFA President’s Corporate Circle Founders Society Our Chapters Leadership & Staff 2 4 10 20 26 33 34 36 38

1
Table of Contents

About Crohn’s disease and ulcerative colitis
Crohn’s disease and ulcerative colitis, known collectively as inflammatory bowel diseases (IBD), are painful, medically incurable digestive diseases. Approximately 1.4 million Americans are afflicted, including over 140,000 children. Most often striking young adults, IBD exacts a heavy toll in acute care, and can often involve multiple surgeries, hospitalizations, and in rare cases, untimely death. Although we have made significant progress in treating Crohn’s disease and ulcerative colitis in recent years, we do not yet have cures or means of prevention.

There has never been a more hopeful time to invest in IBD research.
Crohn’s disease and ulcerative colitis are exceptionally complex diseases involving the human immune system and gastrointestinal tract. Understanding the biological underpinnings of IBD requires research in the scientific fields of immunology, microbiology, biochemistry, and genetics, which have all been targeted by CCFA in our strategic plans and grant programs. The Foundation funds cutting-edge, multi-disciplinary studies at major medical institutions, nurtures investigators at the early stages of their careers, and finances underdeveloped areas of research.

Fiscal 2008: September 1, 2007 — August 31, 2008

Voices of Progress
Dear Friends, There has never been a time to be more committed to the cause of life-changing research in Crohn’s disease and ulcerative colitis. Because of your generous support, we are now witnessing astonishing advances in the understanding of these devastating diseases that inflict such a heavy burden on thousands of families. Forty-two years of Foundation history have demonstrated the power of our donors’ unwavering support. Over four decades, CCFA has become the unmistakable voice for finding answers that will one day lead to a cure. The opportunities have never been greater for transforming the future of over 1.4 million Americans and future generations with Crohn’s disease and ulcerative colitis by investing in cutting-edge research.
2008 was a watershed year for our Foundation. We reached new fundraising and research milestones. In the past fiscal year, we invested $15.5 million in research, roughly two and a half times what we allocated only a couple of years ago. CCFA funded fifty-three research projects this year, an excellent accomplishment in what continues to be a financially challenging environment. CCFA has defined itself by sponsoring the best and brightest researchers over many decades, seeding the field with studies around the mysteries of Crohn’s disease and ulcerative colitis, collectively known as inflammatory bowel diseases (IBD). The model has been a resounding success as the majority of our selected scientists have received continuing grants from the National Institutes of Health to undertake larger and more definitive studies. This strategy has resulted in a very high return on our invested dollars. It also has shaped a strong partnership with the research community that was most apparent in this year of financial challenges.

3
Due to our accelerated research investment in the past year, our portfolio can now boast of two high-profile initiatives. In 2008, the Foundation commenced funding of the CCFA Human Gut Microbiome Initiative and the CCFA Risk Stratification Initiative of our Pediatric Network. These groundbreaking studies, discussed in this annual report, leverage 21st-century scientific and technology breakthroughs to move us forward in our understanding and treatment of IBD. These investments are aligned with our strategic goals of addressing areas of unmet needs for solving the puzzle of IBD, and improving the outlook for all young IBD patients by developing a better standard of care from day one. The CCFA Human Gut Microbiome Initiative moved from a pilot phase into its first and second phases of research in 2008. Dr. Jeffrey Gordon and Dr. Rob Knight have now published five scientific articles sharing new information with the worldwide scientific community. The goal of this prestigious undertaking is to develop labor- and cost-effective tools and framework to enable more scientists to study IBD, which can take the field to a new level of understanding of the role of intestinal microbes. Children have always been at the forefront of the concern of our Foundation. In 2008, CCFA adopted a new acronym, Pro-KIIDS (Pediatric Resource Organization for Kids with Inflammatory Intestinal Digestive Diseases) to symbolize our comprehensive and ambitious approach to pediatric research and care. CCFA has to date invested over $10 million in research, services, and education programs for young IBD patients. CCFA’s Clinical Alliance has made impressive headway in gaining timely information about pregnancy and IBD. However, many more promising studies looking at clinically important questions are waiting in the wings. The work of the Clinical Alliance is crucial because it both provides short-term improvements in patient care and a foundation for applying scientific discoveries to patient-based research. The need for patient support has always been at the core of CCFA’s mission. The rapid uptake in Web-based technology has transformed the field of patient education and support. CCFA’s Information Resource Center (IRC) in its second year launched a community interactive Web site that has drawn over 356,000 visitors. For our younger patients, our new teen Web site — ucandcrohns.org — provides an online resource second to none. The IRC has also discovered an appreciative audience for educational teleconferences and Webcasts and we will be expanding this activity in the future. CCFA’s signature fundraising events launched in 2008, Team Challenge — a half marathon and training program, and Take Steps — a community walk, are proving to be strong contributors to the bottom line. Over 30,000 people participated in these events in 2008, raising $9.5 million dollars. We expect that our entry into the popular social networking site, Facebook, will help drive awareness in FY09. Members will be able to share the cause with networks of friends and colleagues with ease and efficiency. Our advocacy efforts in Washington, D.C. are also supported by online grass-roots strategies for gaining sponsorship for our IBD bill in Congress. In 2008, support continued to grow. In FY08, NIH funded $80 million in IBD research. The NIDDK is the primary site for IBD research and responsible for the Inflammatory Bowel Disease Consortium. The historic discovery of twenty-one new disease-associated genes published in 2008 was the result of their groundbreaking research. We anticipate that the increase of funding from the economic stimulus in FY09 will continue to increase the discoveries in genetic research. This is an exciting time to continue our journey toward curing and preventing Crohn’s disease and ulcerative colitis. The opportunities that we can pursue today are significantly more promising than they were only ten years ago. The potential for efficiencies and productivity based on digital technology is also most encouraging. We recognize our responsibility to you, our generous supporters, to continue to make the best choices in research and fundraising programs. We acknowledge that every donation has moved us ahead in this long and enduring mission to find a cure. Sincerely, President’s Letter

Richard J. Geswell President

Gary Sinderbrand Chairman of the National Board

Research Report
For basic science and clinical research, a time to be hopeful.
Since its inception over forty years ago, CCFA has funded more than 1,100 grants to the most promising researchers in this field. Our cumulative investment of over $136 million has defined these inflammatory bowel diseases and transformed the clinical management and scientific understanding of Crohn’s disease and ulcerative colitis. With the convergence of life science breakthroughs, rapid technological advances in genetic research, and our expanding knowledge of the human gut microbiome, our research dollars can bring us closer to curing or preventing these diseases in more ways than we ever imagined.

5

Research Highlights
CCFA’s National Scientific Advisory Committee and Research Department allocates the Foundation’s grants according to the priorities set in “Challenges in IBD Research,” the Foundation’s strategic plan for research programs. The priorities are determined through continuous reassessment of unmet needs, as science and technology evolve. In 2008, expansion of research support into the areas of the gut microbiome and genetics exemplified the dynamic process of funding research.

investigators. The CCFA community of researchers understands that the continuity of progress toward our common goal requires that we maintain a pipeline of scientific talent. CCFA’s strategy has produced a windfall of discovery in this field. The Foundation provides seed funding to the most promising researchers, who subsequently apply for continuing funding from NIH to expand their pilot work. The success of our process is validated by the fact that over 80% of grant recipients receive funds from NIH to continue their work begun with CCFA support.

Research Report

CCFA Major Research Priorities • Genetics/Immune Profiles/Biomarkers for Prognosis — Clinical research • Microbiome — Basic research • Identification of New Genes and Functional Analysis of Genes — Basic research • Translation of Discovery to Therapy — Clinical research • Immune Cells/Innate Immune Mechanism — Basic research • Epithelial Cells/Innate Immune Mechanism — Basic research • Adaptive Immune Response — Basic research The Value of Partnership Through its research grants, CCFA has nurtured and helped focus the careers of many leading investigators in IBD. These opinion leaders often began their careers as CCFA research fellows. A unique turn of events in 2008 illustrates the exceptional partnership between the Foundation and the research community. With the economic downturn already making itself felt, CCFA received a vital boost in grant funding when new and returning senior researchers returned 10% of their grant funds to CCFA. Through this uncommon gesture of support, the Foundation was able to maintain its funding of 25-30% of research applications received from young

Facts
• Each year, our National Scientific Advisory Committee conducts peer review of over 250 applications for grants. • In 2008, the Foundation set a new record, more than doubling its research grants from only two years ago. • Over 80% of CCFA grant recipients receive further funding from NIH to expand their IBD research, validating our grant selection process.

Progress in Basic Science
Genetic Research In 2001, the first gene associated with Crohn’s disease was identified. In 2008, the number of genes identified and associated with IBD more than tripled, from eleven to an astonishing forty loci. CCFA-funded research was prominent in top scientific journals like Nature, Nature Genetics, and Cell. 2009 and beyond

2008: $15 million

Research investments in the past four years:

2007: $13 million 2006: $10 million 2005: $6.3 million

“In time, for example, microbes may become 21st century biomarkers of disease risk and a treatment’s effectiveness. New treatments may emerge as researchers begin to understand how bacteria attached to the intestinal lining are exposed to our immune systems. It should become possible to influence the structures and operations of our gut communities, and how these communities communicate with our immune system.”
Jonathan Braun, M.D., Ph.D., 2005–2008 Chair of CCFA’s National Scientific Advisory Committee

Scientific publications resulting from this groundbreaking research began to appear in journals in 2008 and shall continue over the next several years. It is anticipated that the resulting insights into intestinal bacteria and their genes will create new leads for tackling the complexities of IBD.

Progress in Clinical Research
A strategic objective of CCFA is to target novel therapeutic approaches through clinical research that benefits patients in the short term. CCFA’s Clinical Alliance and Pediatric Network unite medical professionals from all over the country to make it possible for us to realize this critical goal.

CCFA Human Gut Microbiome Initiative Major discovery in science and medicine often comes when big and bold new ideas take root and have high impact. Recent technology breakthroughs have elevated the field of metagenomics, the study of the genes of microbes, to a new level. Taking the study of IBD to the forefront of metagenomics, the Foundation initiated its largest multi-year research investment in its history in 2008. The CCFA Human Gut Microbiome Initiative, based at the world-renowned Genome Center of Washington University in St. Louis, is under the able direction of Dr. Jeffrey I. Gordon of Washington University, a gastroenterologist and Director of the Center for Genome Sciences, and Dr. Rob Knight, Assistant Professor of Chemistry and Biochemistry at the University of Colorado, an expert in bioinformatics. Through this initiative, the Foundation is aiming to empower more scientists to study the intestinal community of microbes is are believed to play an intrinsic role in the inflammatory bowel diseases. The research team will create accessible tools and techniques that can be shared with the IBD scientific community around the world. In essence, CCFA is seeding the research field for future accomplishments in the field of IBD. In conjunction with CCFA’s Clinical Alliance, the human gut microbiome researchers plan to study identical and non-identical twin pairs, with and without IBD, to further the understanding of human genetics and environment in the development of IBD.

Dr. Bruce Sands, Acting Chief of the Gastrointestinal Unit at the Massachussetts General Hospital in Boston and Chairperson of the CCFA Clinical Alliance. “We can utilize established sites to build patient registries or to develop clinical trials. Researchers would like to look at what treatment works best for individual problems, side effects, and the best order of using drugs. Importantly, our work is free of commercial bias.” CCFA’s Clinical Alliance The Clinical Alliance may well be the only multi-center association for IBD in the world to be initiated and supported by a patient-based foundation.

7
The Alliance was created under the premise that the study of a somewhat uncommon disease like IBD requires multiple clinical sites to produce sufficient data for productive investigations. Although most of the forty-six Alliance members are academic medical centers, community-based medical practices also participate. Pregnancy and IBD Currently, the major initiative of the Alliance is in the area of pregnancy and infant health. It is seeking to answer one of the top questions of all newly diagnosed patients: the impact of IBD and current therapies on pregnancy and outcomes. This is a question for which physicians have only had partial answers at best. In 2008, this initiative, known officially as The National Prospective Pregnancy Registry in Inflammatory Bowel Disease, made significant advances. Led by Uma Mahadevan-Velayos, M.D., at UCSF in San Francisco, the registry began in August 2007 and has enrolled 350 pregnant patients with Crohn’s disease, ulcerative colitis, and indeterminate colitis at thirty Clinical Alliance sites. Preliminary results were presented at the annual Digestive Disease Week meeting in June 2009. The pregnancy registry exemplifies how a multicenter collaborative effort can yield information not available from single institutions. With the advent of new biologic treatments for IBD, there is a critical need for more current information for patients in their reproductive years. With the pregnancy registry, we can now hope to have better answers. In the short term, with additional financial investment, the Clinical Alliance can do more to help physicians and their patients manage IBD more effectively. Research Report

In 2008, CCFA Funded:
• 53 new research projects • 200 active grants

The CCFA Pediatric Network and the Pediatric Risk Stratification Initiative Following our Pediatric Challenges Plan—laid out in 2006—the Foundation is addressing unmet needs in pediatric research and patient care. In 2008, we began to identify our diverse initiatives under the acronym, PRO-KIIDS (Pediatric Resource Organization for Kids with Inflammatory Intestinal Digestive Diseases). Most physicians and scientists see prevention of the onset of IBD as the greatest opportunity for eradicating Crohn’s disease and ulcerative colitis. For the more than 140,000 children afflicted in the United States alone, the need for prevention is even more pressing, as IBD in its most severe forms can irreversibly affect bone development and retard growth. The CCFA Risk Stratification Initiative has been set up to “crack the code” of disease prognosis by identifying measurable risk factors for the complications of severe disease. In 2008, a very committed group of clinical researchers in CCFA’s Pediatric Network laid the foundation for identifying genetic, microbiological, and immunological factors that are predictive of more severe disease within several years. The resulting knowledge will translate into new protocols for individualized approaches to treating IBD in children — based on their risks — and thus preventing severe disease and its lifelong consequences.

If you ask Dr. Mahadevan-Velayos why a pregnancy registry is an idea whose time is now, she is quick to respond: “Without the registry, we will never be able to advise women on the effects that their illness and medications might have on pregnancy outcome and the baby.”

The Pediatric Network plans to bring hundreds of pediatric gastroenterologists and other healthcare professionals from about 40 pediatric centers (USA and Canada) under its administrative umbrella in a clinical research project of unprecedented scope. The Network is chaired by Dr. Subra Kugathasan, Director of Pediatric IBD at Emory Children’s Center and Children’s Hospital of Atlanta. In 2008, Dr. Kugathasan and his colleagues from six other centers successfully initiated a pilot study to demonstrate their capability to execute on all fronts, with a biobank, a data center, and a DNA core laboratory ready for service. The collection and storage of biological samples from all over the country are some of the core functions of the study. A centralized Biospecimen Repository Center is being set up at Emory Children’s Center.

“Ultimately, our goal is to prevent IBD in the next generation. In the short term, we want more effective treatment and total management from day one.
R. Balfour Sartor, M.D., CCFA’s Chief Medical Advisor

The Pediatric Network will enroll eleven hundred patients and identify the risk factors from the biological materials collected in this innovative clinical research study.

Subra Kugathasan, M.D., Chair of Pediatric Network: “For the first time, we are collecting (and banking for future use) biological samples from large prospective patient populations at the time of diagnosis, before any therapies are started. We will bank DNA, blood serum, stool, and tissue biopsies for future IBD research over the next 20 to 30 years. The overall intention is to provide access to this valuable data and biological materials, so that discoveries and breakthroughs can occur. I believe there is no other biobank pertaining to IBD like this in the world, not even at the National Institutes of Health.”

From left to right: R. Balfour Sartor, M.D., Rob Knight, Ph.D., Lloyd Mayer, M.D., Jeffrey I. Gordon, M.D., and Bruce E. Sands, M.D.

9
Research Report

IBD Support, Education, and Advocacy Investments
CCFA is investing in remaining the leading source of unbiased, accurate, and current information related to IBD for patients, families and health professionals. • The CCFA Information Resource Center (IRC), in its second year, assisted 13,000 patients, families, and professionals and distributed over 110,000 pieces of literature. The IRC staff consists of master’s level Information Specialists, a coordinator, and manager of the IRC and public education. The Center responds to 1,250 patient inquiries per month. • Our community Web site, www.ccfacommunity.org, has had more than 356,000 visitors since its inception in February 2008. More than 6,000 people have registered at the site. Surveys indicate that the site is visited weekly by many patients who participate in interactive forums. The Foundation will be enlarging this feature in 2009. • The IRC offered two patient education teleconferences in 2008 reaching 4,186 participants within the USA, supported by corporate funding. This activity is being expanded in 2009. • The Foundation chapters served about 4,000 patients per quarter in 2008 with educational and support programs. We developed a program-in-a-box for launch in 2009 to increase our reach to underserved communities. • Camp Oasis steadily increases enrollment for kids with IBD who can benefit from special summer camp experience. In 2008 we had 1,083 campers, compared to 947 in 2007. • Professional education has seen an increase in membership and attendance at local and national meetings. Attendance at 13 professional education meetings held by our chapters grew to 548 physicians and nurses in 2008. • Our visiting IBD Fellow Program has shaped the career choices of many IBD specialists. In 2008, twelve fellows completed their rotations within specialized IBD departments and five have indicated an interest to specialize in IBD as a result of their experience. • CCFA’s “Advances in IBD 2008” conference attracted 1,031 physicians and nurses, an increase from 805 in 2007. Attendance by nurses doubled with the increased nursing programming offered. • Thanks to a proactive advocacy program, federal support for IBD research at the NIH and CDC continued at $80 million, a 25% increase in a four-year period when global research funding remained relatively flat. The NIDDK is continuing its support of the Inflammatory Bowel Disease Genetics Consortium in light of its great success. • CCFA’s recent annual “Day on the Hill” conference ushered in the introduction of the IBD Research and Awareness Act, while CCFA members met with over 100 legislators from local districts to obtain large bipartisan sponsorship.

Research Awards
A core function of CCFA’s operation is the solicitation and peer review of grant applications from scientists around the world. In recent years, our process has involved an exhaustive peer review of over 250 proposals per fiscal year. The selection and training of reviewers and grant criteria are dynamic and reflect the evolution of science and health care. CCFA grants are awarded based on merit and best fit for the research strategies established by the Foundation. CCFA maintains a strategic plan and periodically reviews the field of IBD to target unmet needs. Our “Challenges in Inflammatory Bowel Diseases” document reflects a multidisciplinary review of the field and is the foundation for advances in the scientific understanding and standard of care of IBD.

11

2008 Research Award Allocations
In 2008, generous donors made it possible to move ahead on crucial research priorities and initiatives, such as the Human Gut Microbiome, the Clinical Alliance, including the Pediatric Research Network, DNA Cell Line Bank, and requests for proposals to identify surrogate markers for IBD. Highlights of funded research included: • The development of the Pediatric Network, a major step toward the objective of managing pediatric disease effectively from day one, through the Risk Stratification Initiative. • Bone development and growth research for children diagnosed with Crohn’s disease, a crucial priority for our youngest patients. • Investigation of colonic dysplasia and the development of colon cancer, as well as surrogate markers for IBD. This includes the search for biological signs that will identify individuals at a higher risk of developing the disease, pinpoint correct diagnosis, and predict how the disease will develop over time. • A prospective study of pregnancy and neonatal outcomes through the CCFA Clinical Alliance to further the goal of improving maternal and infant health. The Clinical Alliance comprises hospital and community health centers from all over the country that cooperate to bring IBD patients into clinically significant studies of Crohn’s and colitis. Their work has the power to transform the day-to-day care of patients. It also provides infrastructure for evaluating the cures of the future. • CCFA’s largest grant in its history, the CCFA Human Gut Microbiome Initiative. As described in this report, the tools and information resulting from an unprecedented probe of gut microbiota will change the course of research into these diseases and may provide new options for disease management. CCFA places high value on the continuity of research by nurturing the next generation of investigators in the field of IBD. The following grant programs are vital for this strategy: Senior Grants Program These grants are awarded to experienced scientists for projects conducted at hospitals, universities, and research laboratories around the world.

Research Training Awards Programs CCFA offers these awards to stimulate careers in independent investigation of IBD. Candidates must be employed by institutions engaged in healthcare and health-related research within the USA and its possessions. Career Development Award Candidates for these awards must have five to ten years of post-doctoral experience, including two years of relevant research experience. The research project must be in the field of IBD. Research Fellowship Awards Candidates must have at least two years of postdoctoral experience. The research project must be in the field of IBD. Student Research Fellowship Awards Candidates are undergraduate, medical, or graduate students at accredited institutions within the United States. They conduct full-time research for a minimum of ten weeks with a mentor investigating a subject relevant to IBD.

Research Awards

A Personalized Opportunity to Make a Difference
CCFA donors of significant gifts have the opportunity to direct their donation to specific studies through a naming opportunity. The CCFA Annual Report lists names of the individual donors to the CCFA Research Program. Donors share in the excitement of meeting the researchers, touring their laboratories, and receiving annual progress reports. If you are interested in participating, you may contact the CCFA National Development Department at 800932-2423, or speak with your local CCFA Chapter.

Grant Opportunities for Researchers
If your field of research applies to IBD, you may apply for a research grant. Call CCFA’s Research and Scientific Department at 800-932-2423, or visit our Web site at www.ccfaprofessionals.org.

MICROBIOME Jay and Ann Davis Richard Davis Daniel and Ellen Crown Lester and Renee Crown Howard and June Esbin Greenspun Family Foundation Arthur and Jayn Marshall Cari Marshall Todd Marshall Susan Molasky Nafees and Shamin Nagy The Honorable and Mrs. Ron Parraguirre Jeffrey I. Gordon, M.D. Washington University School of Medicine, St. Louis, MO CCFA Human Gut Microbiome Initiative Rob Knight, Ph.D. University of Colorado at Boulder CCFA Human Gut Microbiome Initiative

Bruce E. Sands, M.D. Massachusetts General Hospital, Boston, MA OSCCAR: A novel, population-based prospective inception cohort of inflammatory bowel diseases (Funding through the CDC)

PEDIATRIC BONE GROWTH AND SKELETAL HEALTH The Litwin and Swarzman Family Robert N. Cooney, M.D. The Pennsylvania State University, Hershey, PA Mechanisms and therapies for growth failure in intestinal inflammation Lee A. Denson, M.D. Cincinnati Children’s Hospital Medical Center, Cincinnati, OH Immuno-genetics determinants of linear growth in pediatric IBD Serge Ferrari, M.D. University Hospital of Geneva, Geneva, Switzerland Skeletal microstructure and bone fragility in young patients with inflammatory bowel diseases: Novel diagnostic and therapeutic approaches Laura R. McCabe, Ph.D. Michigan State University, East Lansing, MI Mechanisms of IBD suppression of skeletal growth and mineral density Ian R. Sanderson, M.D. University of London, London, England Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I) rhIGF-binding protein-3 complex in children with Crohn’s disease-induced growth retardation Leanne M. Ward, M.D. Children’s Hospital of Eastern Ontario (CHEO) Research Institute, Ottawa, Ontario, Canada The bone mass deficit in pediatric Crohn’s disease: the role of muscle function and cytokines

RESEARCH INITIATIVES CLINICAL RESEARCH ALLIANCE Robert S. Sandler, M.D. University of North Carolina at Chapel Hill, Chapel Hill, NC Clinical Research Alliance: Data Management Center Bruce E. Sands, M.D. Massachusetts General Hospital, Boston, MA Clinical Research Alliance: Administrative

PEDIATRIC NETWORK Edward M. Bernstein Lawrence Finkelstein Mr. and Mrs. Melvin Finkelstein Gordon and Regina Ford Steven and Susan Gringauz Seymour and Carol Levin Foundation Subra Kugathasan, M.D. Emory Children’s Center, Atlanta, GA Risk stratification and identification of immunogenetic markers of complicated disease course in pediatric Crohn’s disease Karis Lovett Clinipace, Research Triangle Park, NC CCFA Pediatrics Data Platform

DYSPLASIA AND CANCER The Ethel Wilson Bowles and Robert Bowles Memorial Fund Leon and Toby Cooperman The Gillman Family: Shaldine, Richard, Sloane, Marc, Andrea, and Scott Mark and Diane Goldman Greater Los Angeles/Orange County Chapter Research Alliance Linda Tallen and David Paul Kane Cancer Educational and Research Foundation F.M. Kirby Foundation Gary and Lanie Sinderbrand Teresa A. Brentnall, M.D. University of Washington School of Medicine, Seattle, WA Biomarkers of colonic dysplasia and cancer in UC patients with PSC Mary P. Bronner, M.D. The Cleveland Clinic Foundation, Cleveland, OH Genomic instability biomarkers of cancer in Crohn’s disease

EPIDEMIOLOGY INITIATIVE Lisa Herrinton, Ph.D. Kaiser Foundation Research Institute, Oakland, CA Practice variation in management of inflammatory bowel diseases (Funding through the CDC)

Donors who have generously sponsored this research are indicated in bold.

13
Lee Goodglick, Ph.D. University of California, Los Angeles, Los Angeles, CA Identification of early detection biomarkers for colon cancer in ulcerative colitis patients using mass spectroscopy protein profiling Antonia R. Sepulveda, M.D., Ph.D. University of Pennsylvania School of Medicine, Philadelphia, PA Inflammatory bowel disease epigenetic markers SENIOR RESEARCH AWARDS Clara Abraham, M.D. Yale University School of Medicine, New Haven, CT LFA-1 and regulatory T cells Saverio Bellusci, Ph.D. The Saban Research Institute of Children’s Hospital Los Angeles, CA Growth factors in gut adaptation Marc Bissonnette, M.D. University of Chicago, Chicago, IL Characterization of a model of chronic ulcerative colitis in AOM/ DSS-treated Hsp722 knock-out mice Richard S. Blumberg, M.D. Brigham & Women’s Hospital, Boston, MA Role of the unfolded protein response in colitis David Boone, Ph.D. University of Chicago, Chicago, IL The role of ubiquitin regulation of intestinal epithelial cell function in IBD Steven R. Brant, M.D. Johns Hopkins University, Baltimore, MD The Mid-Atlantic African-American IBD Study: Exploring racial disparities Elke Cario, M.D. University Hospital of Essen, Essen, Germany Cytoprotective role of toll-like receptor 2 in the intestinal epithelium Shukti Chakravarti, Ph.D. Johns Hopkins University, Baltimore, MD Role of lumican in colitis Eugene B. Chang, M.D. University of Chicago, Chicago, IL Role of OCTN1 and OCTN2 in maintaining intestinal homeostasis and in the pathogenesis of IBD Ru Chen, Ph.D. University of Washington School of Medicine, Seattle, WA Protein signatures for ulcerative colitis (UC) and its risk for colorectal cancer Northwest Chapter Research Alliance Bobby J. Cherayil, M.D. Massachusetts General Hospital, Charlestown, MA The role of indoleamine 2.3 dioxygenase (IDO) in intestinal inflammation Donald A. Cohen, Ph.D. University of Kentucky Medical Center, Lexington, KY Protective role of macrophages in the development of inflammatory bowel diseases

Research Awards

SURROGATE MARKERS The Bruce and Cynthia Sherman Charitable Foundation, Inc. Donald and Mary Jo Lenauer Jed Manocherian Dirk Foell, M.D. University Hospital of Muenster, Muenster, Germany Validation of phagocyte-derived S100A12 as a surrogate marker of intestinal inflammation in inflammatory bowel diseases (IBD) Kenneth E. Hung, M.D., Ph.D. Tufts-New England Medical Center, Boston, MA Mass spectrometry-based discovery of serum Crohn’s disease activity biomarkers Ellen Li, Ph.D. Washington University School of Medicine, St. Louis, MO Molecular determinants of postoperative recurrence of Crohn’s disease Donald and Mary Jo Lenauer

DNA BANK Joseph Drown Foundation F.M. Kirby Foundation Peter and Joan McKee Modell Family Foundation Donald W. Reynolds Foundation Anne and Henry Zarrow Foundation Maxine and Jack Zarrow Family Foundation Kristin Ardlie, Ph.D. Broad Institute, Cambridge, MA Purchase of matched control samples; plating, distribution, and storage of samples for the DNA and Cell Line Bank Lorraine H. Toji, Ph.D. Coriell Cell Repositories, Camden, NJ Establishment and maintenance of a DNA and Cell Line Bank Robert S. Sandler, M.D. University of North Carolina at Chapel Hill, Chapel Hill, NC DNA and Cell Line Bank Data Management Center (formerly entitled “IBD genotyping database project”) Andrew T. Ippoliti, M.D. Cedars-Sinai IBD Center, Los Angeles, CA DNA and Cell Line Bank-Patient Acquisition Center (PAC)

Sean P. Colgan, Ph.D. University of Colorado Health Science Center, Denver, CO Epithelial Ecto-5’-nucleotidase (CD73) and IFNa in IBD Northeast Ohio Chapter Research Initiative Vojo P. Deretic, Ph.D. University of New Mexico, Albuquerque, NM Autophagy in Crohn’s disease Kenneth Dorshkind, Ph.D. University of California, Los Angeles, Los Angeles, CA Intestinal B cell development and function Brian G. Feagan, M.D. Robarts Research Institute, London, Ontario, Canada A phase III randomized, placebo-controlled, double-blind, parallel group, multi-center study to evaluate the safety and efficacy of infliximab in combination with methotrexate for the long-term treatment of Crohn’s disease Hudson H. Freeze, Ph.D. The Burnham Institute, La Jolla, CA Molecular basis of a novel therapeutic antibody for inflammatory bowel diseases Andrew T. Gewirtz, Ph.D. Emory University, Atlanta, GA TLR5-regulation of innate and adaptive immunity in IBD Eileen F. Grady, Ph.D. University of California, San Francisco, San Francisco, CA Dysregulation of receptor signaling leads to intestinal inflammation George H. Greeley, Jr., Ph.D. University of Texas Medical Branch, Galveston, TX Role of apelin in inflammatory bowel diseases Hans Herfarth, M.D., Ph.D. University of North Carolina at Chapel Hill, Chapel Hill, NC Double-blind, placebo-controlled, randomized, multi-center, pilot study on the safety and efficacy of ciprofloxacin for prophylactic prevention of postoperative endoscopic recurrence in Crohn’s disease patients Harvey R. Herschman, Ph.D. University of California, Los Angeles, Los Angeles, CA The role of inflammatory and stromal cell COX-2 production in ulcerative colitis and colitis-associated colon cancer Barbara and Fred Miller Peter D. Higgins, M.D., Ph.D. University of Michigan, Ann Arbor, MI A novel, valid disease activity index for clinical research in ulcerative colitis I-Cheng Ho, M.D., Ph.D. Brigham & Women’s Hospital, Boston, MA Ets-1 as a therapeutic target of Crohn’s disease

Lora V. Hooper, Ph.D. University of Texas Southwestern Medical Center at Dallas, Dallas, TX Interactions between commensal bacteria and yS intraepithelial lymphocytes in mucosal injury Christian Jobin, Ph.D. University of North Carolina, Chapel Hill, NC Role of bacteria in colitis-associated colon cancer Michael Libretti Memorial Research Fund Chang H. Kim, Ph.D. Purdue University, West Lafayette, IN Mechanisms of immune cell trafficking in inflammatory bowel diseases Jan-Michael A. Klapproth, M.D. Emory University, Atlanta, GA Bacterial TNF-alpha inducing effector proteins Stephen M. Krane, M.D. Massachusetts General Hospital, Charlestown, MA Roles of collagenolysis and collagenolytic matrix metalloproteinases in the experimental inflammatory bowel diseases that accompany mucosal injury in mice Juan J. Lafaille, Ph.D. New York University School of Medicine, New York, NY Improving the efficacy of regulatory T cells in inflammatory bowel diseases The Pamela Darnell Research Fund Wayne I. Lencer, M.D. The Children’s Hospital of Boston, Boston, MA FcRn-dependent transepithelial processing of IgG-opsinized microbes and microbial products in the inflammatory response Hongmin Li, Ph.D. Health Research Inc./NYSDOH, Albany, NY Structure and host recognition of the Crohn’s disease-associated protein PfiT Pauline K. Lund, Ph.D. University of North Carolina, Chapel Hill, NC Role of suppressor of cytokine signaling 3 in epithelial repair and tumorgenesis during injury and inflammation Get Your Guts in Gear Averil Ma, M.D. University of California, San Francisco, San Francisco, CA Novel regulation of T cell mediated colitis by a ubiquitin modifying enzyme Lillian Maggio-Price, Ph.D. University of Washington School of Medicine, Seattle, WA Inflammation and TGFB dysregulation in the evolution of colon cancer Uma Mahadevan, M.D. University of California, San Francisco, San Francisco, CA A multicenter national prospective study of pregnancy and neonatal outcomes in women with inflammatory bowel diseases

15
Lloyd Mayer, M.D. Mount Sinai School of Medicine, New York, NY The role of carcinoembryonic antigen in mucosal immunity Mark Mooseker, Ph.D. Yale University School of Medicine, New Haven, CT The enterocyte actin cytoskeleton and maintaining the intestinal mucosal barrier Yuriko Mori, Ph.D. Johns Hopkins University, Baltimore, MD A genome-wide search for novel methylation targets in inflammatory bowel diseases-associated colon cancer Bruce Paster, Ph.D. The Forsyth Institute, Boston, MA Bacterial associations of the gastrointestinal tracts of subjects with Crohn’s disease Marcus Peter, Ph.D. University of Chicago, Chicago, IL A novel role of the “death receptor” Fas as a protector from colitis Scott E. Plevy, M.D. University of North Carolina at Chapel Hill, Chapel Hill, NC Carbon monoxide, cigarette smoking, and IBD D. Brent Polk, M.D. Vanderbilt University School of Medicine, Nashville, TN ErbB-4 regulations of intestinal inflammatory wound healing and repair Lynn Puddington, Ph.D. University of Connecticut Health Center, Farmington, CT Antigen acquired from breast milk induces mucosal regulatory T cells Eyal Raz, M.D. UCSD-The Regents of the University of California, La Jolla, CA PRR-activated dendritic cells regulate experimental colitis Maria Rescigno, Ph.D. European Institute of Oncology, Milan, Italy Study of the defects of TSLP expression in Crohn’s disease patient new therapeutic strategies John D. Rioux, Ph.D. Montreal Heart Institute, Montreal, Quebec, Canada A biological pathway approach to understanding IBD Louisiana/Mississippi Chapter Research Alliance Bruce E. Sands, M.D. Massachusetts General Hospital, Boston, MA Response to infliximab for active ulcerative colitis: A multi-center, prospective assessment of predictors of response to infliximab R. Balfour Sartor, M.D. University of North Carolina at Chapel Hill, Chapel Hill, NC Dietary metal-bacterial interactions in immune-mediated intestinal inflammation Long Island Chapter Research Alliance Suzana D. Savkovic, Ph.D. Evanston Northwestern Healthcare Research Institute, Evanston, IL Cross-communication between intestinal inflammation and tumorigenesis: The role of Foxo3a in intestinal inflammation Cynthia L. Sears, M.D. Johns Hopkins University, Baltimore, MD Defining microbial and immune contributors to pediatric IBD Western Pennsylvania/West Virginia Chapter Research Initiative Mark H. Siegelman, M.D., Ph.D. University of Texas Southwestern Medical Center at Dallas, Dallas, TX Adhesion markers for T cell regulatory activity in inflammatory bowel diseases The William Stamps Farish Fund Shanthi V. Sitaraman, M.D., Ph.D. Emory University, Atlanta, GA Prohibitin: A novel antioxidant molecule Elvin and Janet Price Thomas C. Smyrk, M.D. Mayo Clinic and Foundation, Rochester, MN Investigating the methylation status of genes of interest in UC-CRC: Testing for field effect in non-dysplastic adjacent tissue from colectomy samples to identify diagnostic markers for use in surveillance biopsies Thaddeus S. Stappenbeck, M.D., Ph.D. Washington University School of Medicine, St. Louis, MO Cellular and molecular factors of the epithelial stem cell niche that the colonic mucosal injury response Manjunath N. Swamy, M.D. Texas Tech University Health Sciences Center, El Paso, TX Role of CD27-CD70 costimulatory pathway in inflammatory bowel diseases Eva Szigethy, M.D., Ph.D. University of Pittsburgh, Pittsburgh, PA Improving quality of life using cognitive behavioral therapy in depressed youth with inflammatory bowel diseases Cornelis P. Terhorst, Ph.D. Beth Israel Deaconess Medical Center, Boston, MA Study of CD84 induced innate and adaptive immune responses in experimental colitis Michael J. Wannemuehler, Ph.D. Iowa State University, Ames, IA Microbial perturbation of mucosal homeostasis: Predisposition to colitis Ifor Williams, M.D., Ph.D. Emory University, Atlanta, GA Regulation of organized intestinal lymphoid tissues by trance/rankl Mei X. Wu, M.D., Ph.D. Massachusetts General Hospital, Boston, MA Smad phosphatase’s regulation and function in T cells

Research Awards

Lijun Xia, M.D., Ph.D. Oklahoma Medical Research Foundation, Oklahoma City, OK Role of intestinal O-glycans in the pathogenesis of ulcerative colitis Huabao Xiong, M.D., Ph.D. Mount Sinai School of Medicine, New York, NY The essential role of IFN consensus sequence-binding protein in the development of colitis Fang Yan, M.D., Ph.D. Vanderbilt University School of Medicine, Nashville, TN Regulatory effects of probiotic-derived soluble proteins on colitis Guang-Yu Yang, M.D., Ph.D. Northwestern University, Chicago, IL Inositol and chemoprevention of ulcerative colitis-induced carcinogenesis Wei-Ping Zeng, Ph.D. University of Rochester School of Medicine, Rochester, NY Role of Foxp3 in inflammatory bowel diseases

Neera Gupta, M.D. University of California, San Francisco, San Francisco, CA Gender differences in growth in pediatric patients with Crohn’s disease CCFA’S Co-Sponsored Young Investigator Award Children’s Digestive Health and Nutrition Foundation (Co-Sponsored Award through NASPGHAN) Xiaonan Han, Ph.D. Cincinnati Children’s Hospital Medical Center, Cincinnati, OH Characterization of STAT5b as a novel therapeutic target in Crohn’s disease Simon P. Hogan, Ph.D. Cincinnati Children’s Hospital Medical Center, Cincinnati, OH Eosinophils and pediatric inflammatory bowel diseases Eric Houpt, M.D. University of Virginia/Digestive Health Ctr, Charlottesville, VA Control of innate intestinal inflammation in mice Li-Chung Hsu, Ph.D. University of California, San Francisco, La Jolla, CA The molecular mechanism of NOD2 in the pathogenesis of Crohn’s Disease Andrei I. Ivanov, Ph.D. University of Rochester School of Medicine, Rochester, NY The role of endocytic recycling of junctional proteins during mucosal restitution IBD Matam V. Kumar, Ph.D. Emory University, Atlanta, GA Role of adaptive immunity in the development of spontaneous colitis in toll-like receptor-5 (TLR-5) deficient mice Sarkis K. Mazmanian, Ph.D. California Institute of Technology, Pasadena, CA The molecular mechanism of symbiotic commensal protection against colitis Christine McDonald, Ph.D. The Cleveland Clinic Foundation, Cleveland, OH Molecular mechanisms of activation and regulation of the Crohn’s disease associated protein NOD2 J. Rodrigo Mora, M.D., Ph.D. Massachusetts General Hospital, Boston, MA Microenvironmental programming of intestinal dendritic cells to imprint gut-tropism in lymphocytes Masako Murai, M.D., Ph.D. La Jolla Institute for Allergy & Immunology, La Jolla, CA Prevention of colitis mediated by IL-10 and regulatory T cells Brian M. Necela, Ph.D. Mayo Clinic Jacksonville, Jacksonville, FL Cellular and molecular targets essential for the protection against the development of ulcerative colitis

CAREER DEVELOPMENT AWARDS Laetitia Charrier, Ph.D. University of Pennsylvania School of Medicine, Philadelphia, PA Roles of ADAM-15 in inflammatory bowel diseases Matthew A. Ciorba, M.D. Washington University School of Medicine, St. Louis, MO Indoleamine 2,3 dioxygenase (IDO) in intestinal inflammation: Assessment of IDO induction agents to abrogate colitis and correlation of IDO activity to human inflammatory bowel diseases Beckley K. Davis, Ph.D. University of North Carolina at Chapel Hill, Chapel Hill, NC Nucleotide binding in NLR-Mediated inflammation and carcinogenesis Timothy L. Denning, Ph.D. Emory University, Atlanta, GA The role of antigen-presenting cells in modulating intestinal immune responses Raja Fayad, M.D. University of Illinois at Chicago, Chicago, IL Role of adipokines in inflammatory bowel diseases Masayuki Fukata, M.D., Ph.D. University of Miami, Miami, FL The role of TLR4 signaling in colitis-associated cancer Neera Gupta, M.D. University of California, San Francisco, San Francisco, CA Gender differences in growth in pediatric patients with Crohn’s disease

17
Darrell B. O’Quinn, Ph.D. University of Alabama at Birmingham, Birmingham, AL Functional roles of IL-6 and IL-23 in regulating Th17-mediated colitis models Alabama/Northwest Florida Chapter Research Alliance Lance Robert McLendon Memorial Tournament Helen Pappa, M.D. The Children’s Hospital of Boston, Boston, MA Optimization of vitamin D status and its impact on bone health and disease outcomes in young patients with inflammatory bowel diseases Steven Polyak, M.D. University of Florida, Gainesville, FL Targeted gene delivery to the intestinal epithelium for the study and treatment of colitis Florida Chapter Research Alliance The Retirement Research Foundation Seema Saksena, Ph.D. University of Illinois at Chicago, Chicago, IL Regulation of intestinal chloride absorption by neuropeptide Y Corey A. Siegel, M.D. Dartmouth Medical School, Lebanon, NH Risk communication in Crohn’s disease Kris A. Steinbrecher, Ph.D. Cincinnati Children’s Hospital Medical Center, Cincinnati, OH Role of NF-kB/GSK-3-mediated gene expression in initiation of inflammatory bowel diseases Michael C. Stephens, M.D. Medical College of Wisconsin, Milwaukee, WI ABC transporter pharmacogenetics impact on thiopurine therapy CCFA’S Co-Sponsored Young Investigator Award Children’s Digestive Health and Nutrition Foundation (Co-Sponsored Award through NASPGHAN) Fernando Velayos, M.D. University of California, San Francisco, San Francisco, CA 5-ASA use and risk of colorectal dysplasia and cancer among ulcerative colitis patients You-Qing Zhang, Ph.D. University of California, San Diego, La Jolla, CA Involvement of activin signaling in the pathogenesis of inflammatory bowel diseases Zili Zhang, M.D., Ph.D. Oregon Health and Science University, Portland, OR OXO40 and th17 cell activation in inflammatory bowel diseases Eric L. Campbell, Ph.D. University of Colorado Health Science Center, Denver, CO Mechanisms of intestinal inflammation resolution via lipid mediators Rocky Mountain Chapter Research Alliance Bindu P. Chandrasekharan, Ph.D. Emory University, Atlanta, GA Neuropeptide Y and neurogenic inflammation in inflammatory bowel diseases Xinhua Chen, Ph.D. Beth Israel Deaconess Medical Center, Boston, MA Mechanisms of protective role of saccharomyces boulardii in intestinal inflammation and neoplasia James D. Ireland, IV Alex Chung Kyu Chin, Ph.D. Emory University, Atlanta, GA Effect of neutrophil transmigration and epithelial pathophysiology in inflammatory bowel diseases Guillaume Dalmasso, Ph.D. Emory University, Atlanta, GA Role of the anti-inflammatory tripeptide KPV in IBD Sara Dann, Ph.D. University of Texas Medical Branch, Galveston, TX Novel strategy of probiotic intervention in intestinal inflammation Lopamudra Das, Ph.D. Case Western Reserve University, Cleveland, OH Mechanism of TGF-B-Mediated suppression of T cell receptor signal transduction in IBD Porfirio N. Dominguez, Ph.D. Emory University, Atlanta, GA Role of desmosomal cadherins in the regulation of the intestinal epithelial barrier in IBD Benjamin Faustin, Ph.D. The Burnham Institute, La Jolla, CA Biochemical mechanisms regulating NAC function in IL-1b processing Pallavi Garg, Ph.D. Emory University, Atlanta, GA Characterization of metalloproteinase-2 in inflammatory bowel diseases Mordechay Gerlic, Ph.D. The Burnham Institute, La Jolla, CA Mechanisms of NALP1 inflammasome regulation by Bcl-2 and Bcl-XL Ana Belen Blazquez Gonzalez, Ph.D. Mount Sinai School of Medicine, New York, NY The role of thymic stromal lymphopoietin (TSLP) in the homeostatis of mucosal immunity

Research Awards

RESEARCH FELLOWSHIP AWARDS Abraham L. Brass, M.D., Ph.D. Massachusetts General Hospital, Boston, MA An RNAi strategy for the identification of factors required for TNF-a induced apoptosis

Helen Goodridge, Ph.D. Cedars-Sinai IBD Center, Los Angeles, CA The role of NFAT in shaping innate inflammatory responses Sergei Grivennikov, Ph.D. UCSD-The Regents of the University of California, La Jolla, CA Role of cytokines and adaptive immunity in chronic colon inflammation and tumorigenesis Matija Hedl, Ph.D. Yale University School of Medicine, New Haven, CT NOD2-mediated self-tolerance and cross-tolerance to toll-like receptors 2 and 4 Shien Hu, M.D., Ph.D. University of Chicago, Chicago, IL Post-transcriptional regulation of heat shock proteins by pro-inflammatory cytokines: Contribution to IBD pathogenesis Ivaylo Ivanov, Ph.D. New York University School of Medicine, New York, NY Role of RORyt+ cells and cryptopatches in the pathogenesis of IBD and mucosal immunity Rheinallt M. Jones, Ph.D. Emory University, Atlanta, GA A novel genetic system to study host bacterial interactions Dr. and Mrs. James F. Rooney Iordanis Karagiannidis, Ph.D. University of California, Los Angeles, Los Angeles, CA SP-mediated involvement of mesenteric fat tissue in the development of inflammatory bowel diseases Hon Wai Koon, Ph.D. University of California, Los Angeles, Los Angeles, CA Mechanisms of the healing effects of substance P in intestinal inflammation Narendra Kumar, Ph.D. Texas A&M Research Foundation, Kingsville, TX Role of JAK3-villin interaction in the restitution of intestinal epithelial cells Courtney C. Kurtz, Ph.D. University of Virginia/Digestive Health Ctr, Charlottesville, VA The role of A2AAR in T cell mediated colitis Jessica J. Lee, M.D. The Children’s Hospital of Boston, Boston, MA Genetics of growth failure in pediatric inflammatory bowel diseases Ronald A. Krancer Research Award Katsuyoshi Matsuoka, M.D., Ph.D. University of North Carolina at Chapel Hill, Chapel Hill, NC Endogenous danger signals in IBD Francoise Meylan, Ph.D. National Institutes of Health, NIAMS, Bethesda, MD Role of TL1A-DR3 TNF-family interactions in inflammatory bowel diseases

Aylwin Ng, Ph.D. Massachusetts General Hospital, Boston, MA Elucidating functional network modules and novel effectors in TLR/ NOD-LPP-mediated signal transduction relevant to IBD pathogenesis using integrative systems and bioinformatics approaches Marie Anne O’Donnell, Ph.D. Mount Sinai School of Medicine, New York, NY Regulation of TNF-induced NF-Kb activation and cell death by ubiquitination of RIP Shigeru Oshima, M.D., Ph.D. University of California, San Francisco, San Francisco, CA Regulation of ubiquitylation and T cell mediated colitis Dmitry V. Ostanin, Ph.D. Louisiana State University Health Sciences Center, Shreveport, LA Roles of T-cell-associated Alpha4 integrins in the pathogenesis of chronic colitis Louisiana/Mississippi Chapter Research Initiative Yunji Park, Ph.D. La Jolla Institute for Allergy & Immunology, La Jolla, CA Role of mucosal dendritic cells in the immune regulation and pathogenesis of gut inflammation Iryna V. Pinchuk, Ph.D. University of Texas Medical Branch, Galveston, TX Colonic myofibroblasts-T cells interactions: Implication in immunopathogenesis of ulcerative colitis Ki-Jong Rhee, Ph.D. Johns Hopkins University, Baltimore, MD Murine model of colonic inflammation by enterotoxigenic bacteroides fragilis Javier R. Ros, Ph.D. Beth Israel Deaconess Medical Center, Boston, MA Role of the cell surface receptor SLAMF6 (Ly108) in experimental colitis Get Your Guts in Gear Nikolayevich Samarin, Ph.D. Emory University, Atlanta, GA Regulation of epithelial apical junctional complex in IBD Le Shen, M.D., Ph.D. University of Chicago, Chicago, IL Epithelial tight junction regulation and immune activation in IBD Michael McAteer Memorial Research Fund Ken Sugimoto, M.D., Ph.D. Massachusetts General Hospital, Boston, MA Role of interleukin-22 in epithelial cell function and colitis Michael Verzi, Ph.D. Dana-Farber Cancer Institute, Boston, MA Understanding intestinal epithelial cell function by defining the Cdx2

19
Flavia A. Wald, Ph.D. University of Miami, Miami, FL Biogenesis of the apical ezrin scaffold and diarrheal disorders Caihong Wang, Ph.D. Washington University School of Medicine, St. Louis, MO The role of a4 integrins in isolated lymphoid follicles formation Yutao Yan, Ph.D. Emory University, Atlanta, GA Role of integrin-associated protein CD98 in intestinal permeability Sebastian Zeissig, M.D. Brigham & Women’s Hospital, Boston, MA Characterization of natural killer T cells in the murine intestine David Alexander Ziring, M.D. University of California, Los Angeles, Los Angeles, CA Manipulation of immunoregulatory B cells in colitis Daniel E. Schloss Massachusetts General Hospital, Charlestown, MA The role of cystic fibrosis trans-membrane receptor in intestinal inflammation Get Your Guts in Gear Scott M. Tanner University of Alabama at Birmingham, Birmingham, AL Effects of estrogen on regulatory T cell function in a mouse model of colitis Charles Vainder Evanston Northwestern Research Institute, Evanston, IL Regulation of tumor suppressor Foxo3a by lipopolysaccharide in intestinal epithelial cells and its contribution in IL-8 expression In honor of Christopher D. Maier, Sr. Tomas Vanagunas Northwestern University, Chicago, IL Examination of beta catenin signaling in IBD Kaitlin Wanta Northwestern University, Chicago, IL Growth factor induced stem cell activation in colitis Warren and Roberta Sirzyk and Family Randolph D. Winnegar Northwestern University, Chicago, IL The role of inositol in colitis induced cancer

Research Awards

STUDENT RESEARCH FELLOWSHIP AWARDS Balaji Ayyar Case Western Reserve University, Cleveland, OH Rho-GTPase regulation of control and IBD LPT migration through control and IBD extracellular matrix Get Your Guts in Gear Swathi Eluri Johns Hopkins University, Baltimore, MD Can differential expression of SLAP and betacellulin genes identified by gene array be used for predictive biomarkers for IBD-associated colon cancer The George Kitzes Student Research Grant Yoon-Jung Mickey Hyun Washington University School of Medicine, St. Louis, MO Indoleamine 2,3 dioxygenase in a chronic model of colitis Aaron Kyle Jenkins Emory University, Atlanta, GA Transcriptional inhibition of prohibitin by TNF-alpha Get Your Guts in Gear Allyson McLoed Massachusetts General Hospital, Boston, MA Investigation of the effect of helminth on epithelial barrier function Get Your Guts in Gear Amy Petzel University of Chicago, Chicago, IL The grading of inflammation in patients with ulcerative colitis by symptoms, serology, histology, optical coherence tomography, fecal marker, and endoscopy Get Your Guts in Gear Steven Russo University of North Carolina at Chapel Hill, Chapel Hill, NC Innate immune defects and IBD in P13 kinase in p110δ mutant Get Your Guts in Gear

WORKSHOPS/CONFERENCES Mark H. Epstein, Sc.D. Society for Mucosal Immunology, Bethesda, MD Antigen recognition at mucosal surfaces: Implications for allergic, inflammatory and immunologic diseases. Satellite symposium for FOCIS 2008 meeting Peter B. Ernst, Ph.D. University of Virginia, Charlottesville, VA Microbes and mucosal immunity–2008 Claudio Fiocchi, M.D. The Cleveland Clinic Foundation, Cleveland, OH Second International Symposium on pediatric IBD

Financial Statements
Report from the Treasurer
The Crohn’s & Colitis Foundation of America (CCFA) achieved revenue of $42.9 million during the fiscal year ended August 31, 2008. Our generous and committed donors made it possible to reach new goals even as the economic headwinds were gaining force. We acknowledge all of those who kept the Foundation on its mission course, allowing us to provide research, education, and support services of the highest quality. In 2008, we allocated more than $34.1 million to mission-critical programs. More than 79.3 cents of every dollar spent by CCFA went to research, education, and patient support. As always, our dedication to careful stewardship met the highest standards of organizations that monitor charities. CCFA again earned an “A” rating from the American Institute of Philanthropy (www.charitywatch.org) and met the 20 Standards of Accountability of the Better Business Bureau’s Wise Giving Alliance. I welcome your inquiries concerning CCFA’s financial results. For more information, please contact the Foundation’s National Headquarters.

Louis Plung Treasurer

21
Financial Statements
Grant Thornton LLP US member firm of Grant Thornton International, Ltd.

Report of Independent Certified Public Accountants National Board of Trustees Crohn’s & Colitis Foundation of America, Inc. We have audited the accompanying statements of financial position of the Crohn’s & Colitis Foundation of America, Inc. (the Foundation) as of August 31, 2008 and 2007, and the related statements of activities, cash flows and functional expenses for the years then ended. These financial statements are the responsibility of the Foundation’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America as established by the American Institute of Certified Public Accountants. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and signifi-

cant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Crohn’s & Colitis Foundation of America, Inc. as of August 31, 2008 and 2007, and the changes in its net assets and cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

Grant Thornton LLP
Philadelphia, Pennsylvania April 15, 2009

STATEMENTS OF CASH FLOWS For the the year ended August 31,

2008

2007

STATEMENTS OF FINANCIAL POSITION August 31,

2008
ASSETS Cash and cash equivalents Pledges receivable, net Prepaid expenses and other assets Investments Charitable gift annuities Charitable remainder trusts Furniture, equipment, and leasehold improvements, net Total assets $4,045,507 5,195,731 1,154,267 11,126,530 295,422 311,920

2007
$3,521,941 5,483,929 784,249 13,908,671 287,727 341,872

1,292,861 1,028,237 $23,157,614 $25,621,250

LIABILITIES AND NET ASSETS Accounts payable and accrued expenses $1,679,639 8,641,721 Research grants payable 243,798 Gift annuity liability Deferred revenue and 795,020 refundable advances 218,491 Deferred rent 37,121 Capitalized lease obligation 11,615,790 Total liabilities Net assets Unrestricted Temporarily restricted Total net assets Total liabilities and net assets

$1,575,746 10,409,191 288,172 1,434,336 178,347 89,091 13,914,883

6,120,785 5,421,039

5,226,115 6,480,252

11,706,367 11,541,824 $23,157,614 $25,621,250

Cash flows from operating activities $(164,543) $1,010,721 Change in net assets Adjustments to reconcile change in net assets to net cash and cash equivalents used in operating activities 433,281 427,023 Depreciation and amortization 40,144 36,784 Deferred rent Net realized and unrealized loss (gain) 238,507 (759,530) on investments 29,952 (22,831) Charitable remainder trusts 61,752 145,000 Provisions for doubtful accounts Changes in operating assets and liabilities 226,446 (3,000,258) Pledges receivable 588,618 Prepaid expenses and other assets (370,018) Accounts payable and 103,893 (560,397) accrued expenses (1,767,470) 456,411 Research grants payable Deferred revenue and (639,316) 307,645 refundable advances (27,644) (23,355) Charitable gift annuities Net cash and cash equivalents (used in) (1,835,016) (1,394,169) operating activities Cash flows from investing activities (13,249,426) (26,379,607) Purchases of investments 15,828,635 28,574,564 Proceeds from sale of investments (488,373) Purchases of furniture and equipment (168,657) Net cash and cash equivalents provided 2,410,552 1,706,584 by investing activities Cash flows from financing activities – 148,485 Borrowings under capital lease (51,970) (59,394) Repayment of capital lease obligation Net cash and cash equivalents (used in) (51,970) 89,091 provided by financing activities Net increase in cash and 523,566 401,506 cash equivalents Cash and cash equivalents, 3,521,941 3,120,435 beginning of year $3,521,941 Cash and cash equivalents, end of year $4,045,507 The accompanying notes are an integral part of these statements.

The accompanying notes are an integral part of these statements.

STATEMENTS OF ACTIVITIES For the year ended August 31, 2008 Temporarily Restricted 2007

Unrestricted
Contributions, other income and reclassifications Contributions Contributions from individuals, foundations and corporations Contributed airtime Special events revenue Less: direct benefit to donor costs Net special events revenue Total contributions Other income (loss) Interest and dividend income Net realized and unrealized gain (loss) on investments Federal grant revenue Other Total other income Total contributions and other income Net assets released from restrictions Total contributions, other income and reclassifications Expenses Program services Research Health professional education and public information Total program services Supporting services Management and general Fund-raising Total supporting services Total expenses

Total

Total

$20,127,208 1,690,983 14,525,689 (4,505,736) 10,019,953 31,838,144

$10,478,181 – – – – 10,478,181

$30,605,389 1,690,983 14,525,689 (4,505,736) 10,019,953 42,316,325

$23,152,851 3,965,173 16,506,647 (3,499,651) 13,006,996 40,125,020

168,193 (238,507) 509,064 95,168 533,918 32,372,062 11,537,394 43,909,456

– – – – – 10,478,181 (11,537,394) (1,059,213)

168,193 (238,507) 509,064 95,168 533,918 42,850,243 – 42,850,243

527,352 759,530 369,081 207,531 1,863,494 41,988,514 – 41,988,514

14,637,796 19,489,496 34,127,292

– – –

14,637,796 19,489,496 34,127,292

15,460,374 18,125,854 33,586,228

4,385,008 4,502,486 8,887,494 43,014,786

– – – –

4,385,008 4,502,486 8,887,494 43,014,786

4,164,164 3,227,401 7,391,565 40,977,793

Change in net assets Net assets, beginning of year Net assets, end of year

894,670 5,226,115 $6,120,785

(1,059,213) 6,480,252 $5,421,039

(164,543) 11,706,367 $11,541,824

1,010,721 10,695,646 $11,706,367

The accompanying notes are an integral part of these statements.

2008 ALLOCATION OF EXPENSE DOLLARS

Administration: 10.2%
(Management and general)

Program Services: 79.3% Fundraising: 10.5%

23
STATEMENTS OF FUNCTIONAL EXPENSES
Year Ended August 31,

Financial Statements

2008
Program Services Health professional education and public information Supporting Services

2007

Research

Total

Management Direct and benefit to Fundraising donor costs general $ – $ – $

Total

Total $14,444,464 11,295,468 5,730,679 3,965,173 1,715,510 1,232,136 966,244 2,000,587 310,033 625,265 583,079 568,471 145,000 900,809

Research grants $15,508,006 $ and awards – $15,508,006 Salaries and related 879,984 expenses 9,627,207 8,747,223 (30,278) Contract services and fees 1,616,462 1,646,740 – Contributed airtime 1,690,983 1,690,983 Publications and related 74,765 printed materials 1,365,248 1,290,483 43,675 Occupancy costs 862,921 819,246 50,415 Postage 907,306 856,891 Conferences, conventions 398,300 and meetings 2,335,776 1,937,476 Telephone and 12,128 communications 216,547 204,419 55,511 Travel 591,129 535,618 Office supplies 19,914 and expenses 329,640 309,726 19,216 Data processing 391,129 371,913 Provision for doubtful 2,038 accounts 40,263 38,225 41,944 Other expenses 808,726 766,782 Total expenses before depreciation Depreciation and amortization of fixed assets Total functional expenses

– $15,508,006 14,087,981 6,070,315 1,690,983 2,218,700 1,323,499 1,366,599 3,132,530 328,298 851,675 869,017 593,773 61,752 1,435,896

2,200,905 357,054 – 349,073 227,245 226,611 364,879 55,137 128,551 82,466 99,983 10,603 210,689

2,259,869 366,620 – 358,425 233,333 232,682 374,655 56,614 131,995 84,675 102,661 10,886 216,334

– 3,730,179 – 145,954 – – 57,220 – – 372,236 – – 200,147

17,075,618

19,215,725

36,291,343

4,313,196

4,428,749

4,505,736

49,539,024

44,482,918

13,961 17,089,579

273,771 19,489,496

287,732 36,579,075

71,812 4,385,008

73,737 4,502,486

– 4,505,736

433,281 49,972,305

427,023 44,909,941

Less: Provision for grant terminations, refunds, relinquishments and accruals (2,451,783) Direct benefit to donor costs of special events – Total expenses reported by function on the statement of activities

– –

(2,451,783) –

– –

– –

– (4,505,736)

(2,451,783) (4,505,736)

(432,497) (3,499,651)

$14,637,796 $19,489,496 $34,127,292 $4,385,008 $4,502,486

$

– $43,014,786

$40,977,793

The accompanying notes are an integral part of these statements.

NOTE A. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES 1. Organization The Crohn’s & Colitis Foundation of America, Inc. (the Foundation) is a not-for-profit organization founded in 1965. The Foundation’s mission is to cure Crohn’s disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases. The Foundation has its headquarters in New York City (the National Office) and has 41 Chapters (the Chapters) and one volunteer affiliate. 2. Basis of Presentation The financial statements of the Foundation have been prepared in conformity with accounting principles generally accepted in the United States of America and in accordance with the provisions of Statement of Financial Accounting Standards (SFAS) No. 117, Financial Statements of Not-for-Profit Organizations. SFAS No. 117 requires that net assets and revenues, gains, expenses and losses be classified as unrestricted, temporarily restricted or permanently restricted based on the existence or absence of donor-imposed restrictions as follows: Unrestricted - Net assets that are not subject to donor-imposed stipulations. Unrestricted net assets represent resources that are available for support of operations, including resources for capital expenditures. Temporarily restricted - Net assets subject to donor-imposed restrictions. Temporarily restricted net assets include amounts that are restricted by donors for particular research projects or education programs, or are restricted as to the timing of use. Permanently restricted - Net assets subject to donor-imposed stipulations that are maintained permanently by the Foundation. There were no permanently restricted net assets at August 31, 2008 and 2007. 3. Cash and Cash Equivalents The Foundation considers highly liquid financial instruments purchased with a maturity of three months or less when purchased, except those held in its investment portfolio, to be cash equivalents. The Foundation maintains cash accounts, which, at times, may exceed federally insured limits. The Foundation has not experienced any losses from maintaining cash accounts in excess of federally insured limits. Management believes that it is not exposed to any significant credit risk on its cash accounts. 4. Contributions and Pledges Receivable Unconditional contributions, including cash, promises to give, and certain contributed services, gifts in-kind and other assets are recorded as revenue at fair value when received. Conditional contributions are recorded when the conditions on which they depend are substantially met. Contributions are recorded, net of estimated uncollectible amounts. Contributions with restrictions met in the same reporting period as received are recorded as unrestricted contributions. Unconditional pledges that are expected to be collected within one year are recorded at their net realizable value. Unconditional pledges that are expected to be collected in future years are recorded at the present value of their estimated future cash flows. Amortization of the related discounts is included in contributions revenue. 5. Allowance for Doubtful Accounts The Foundation maintains an allowance for doubtful accounts for estimated losses that may result from the inability of its donors to make payments. Such allowances are based upon several factors, including, but not limited to, historical experience and the financial condition of its donors. 6. Investments and Investment Income Investments in equity securities and mutual funds with readily determined fair values and all debt securities are recorded at fair value. Fair value is determined based upon quoted market prices. Investment sales and purchases are determined by the specific identification method. Changes in market value of investments are recognized as increases or decreases in unrestricted net assets unless their use is temporarily restricted by explicit donor stipulations or by law. Alternative investments (limited liability companies) are stated at fair value as estimated in an unquoted market. Individual investment holdings within the alternative investments may include investments in both nonmarketable and market-traded securities. Fair value of the alternative investments is determined by management based on information provided by the investment manager. Values may be based on estimates that require varying degrees of judgment for investments where readily available fair values do not exist. Generally, fair value reflects net contributions to the investee and an ownership share of realized and unrealized investment income and expenses. Investments in such funds do carry certain risks including lack of regulatory oversight, interest rate risk and market risk. Due to the level of risk associated with these investments, it is at least reasonably possible that changes in risk factors in the near term would affect amounts reported on the statement of financial position. The Foundation invests in three limited liability companies, which are “funds of funds” (the Funds). The first of these funds (M2) invests mostly in a group of portfolio managers who primarily employ long/short equity strategies, including those involving foreign issuers. The second fund (Event Fund) deploys its assets among a group of portfolio managers, primarily investing in securities and other instruments, the market value of which is expected to be meaningfully affected by an anticipated event, including distressed securities and long/short equity. The third fund (Credit Recovery Fund) has as its investment objective the maximization of total return over the long term, by deploying its assets primarily among a select group of portfolio managers, who invest in companies that have experienced, or are currently experiencing, financial difficulties as a result of deteriorating operations, adverse legal judgments, or other events, which may adversely impact their credit standing, thus taking advantage of market opportunities and pricing inefficiencies between the perceived value of an obligation and its market value. Income earned from investments, including realized and unrealized gains and losses, is recorded on the net asset class owning the assets, based on the trade dates for the investments. 7. Charitable Gift Annuities The Foundation has several charitable gift annuities which are arrangements between donors and the Foundation in which the donors contribute assets to the Foundation in exchange for a promise by the Foundation to pay a fixed amount for a specified period of time to the donors or to individuals or organizations designated by the donors. The fair value of the asset is recorded as a charitable gift annuity and the corresponding liability to the donors is recorded as a gift annuity liability at the present value of its future payments in the statement of financial position. 8. Charitable Remainder Trusts The Foundation has been named as the sole beneficiary in several charitable remainder trusts held by third party trustees. A charitable remainder trust is an arrangement in which a donor establishes a trust with specified distributions to be made to a designated beneficiary or beneficiaries over the trust’s term. The Foundation will receive its share of the assets remaining upon the termination of the charitable remainder trust. The Foundation has recorded the estimated present value of its interest in the trusts’ assets as charitable remainder trusts and contribution income, in accordance with the terms of the trusts. 9. Furniture, Equipment and Leasehold Improvements Furniture and equipment are recorded at cost or, if donated, at fair value on the date received. Depreciation is computed using the straight-line basis over the estimated useful lives of the assets ranging from three to ten years. Leasehold improvements are amortized over the remaining lease term or the estimated life of the improvements, whichever is shorter.

10. Research Grants Payable The Foundation records appropriations for research grants as a liability and expense after approval by the National Board of Trustees based upon (i) the recommendations of the Board’s advisory committees called the National Scientific Advisory Committee’s Grants Review Committee, the Research Training Awards Program Committee the Research Initiatives Committee, and any appropriate ad hoc review committees, (the Review Committees); and (ii) the availability of funding. Grants are approved for a one year term with conditional annual renewal periods up to two years. The only exceptions are the core administrative and data management centers for both the Clinical Research Alliance and DNA Bank, which are long-term commitments. However, these awards are subject to existing grant policies and procedures, and progress reports are reviewed annually in accordance with these policies. The grants are conditional based upon the receipt, review and approval of annual progress reporting from the grant recipients by the Review Committees. The annual grants are disbursed quarterly over the period for which they have been approved. Conditional grants are recognized in the period in which the terms of the conditions are met. 11. Refundable Advances The Foundation receives cash in advance of special events that are to be held after the statement of financial position date. These amounts are deferred until the event occurs, since they are refundable if the event is subsequently canceled. 12. Contributed Airtime The Foundation receives considerable in-kind contributions primarily in the form of donated public service announcements on television and radio stations. The value of such in-kind contributions, based upon information provided by third-party media services, is reflected in the accompanying statement of activities as contributed airtime revenue and health professional education and public information program service expense. 13. Volunteers Other than the Committees, a number of volunteers, including members of the National Board of Trustees, have made significant contributions of time to the Foundation’s policy-making, program and support functions. The value of this contributed time does not meet the criteria for recognition of contributed services contained in SFAS No. 116, Accounting for Contributions Received and Contributions Made, and accordingly, is not reflected in the accompanying statement of activities. 14. Tax-Exempt Status The Foundation is a not-for-profit voluntary health organization exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code (the Code) and has been classified as a publicly supported charitable organization under Section 509(a)(1) of the Code and qualifies for the maximum charitable contribution deduction by donors. Contributions to the Foundation are tax deductible within the limitations prescribed by the Code. The Foundation is also exempt from state and local taxes under similar statutes. 15. Functional Allocation of Expenses Expenses that can be directly identified with the program or supporting service to which they relate are charged accordingly. The costs of providing various programs and supporting services have been summarized on a functional basis in the statement of activities. Accordingly, certain costs have been allocated among the programs and supporting services benefited. 16. Use of Estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant management estimates and assumptions relate to the determination of allowances for doubtful accounts for pledges receivable, alternative investment values, functional allocation of expenses, the present value of the Foundation’s assets in charitable remainder trusts and useful lives of fixed assets. Actual results could differ from those estimates. 17. Pending New Accounting Pronouncements In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements. This new standard provides guidance for using fair value to measure assets and liabilities. SFAS No. 157 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value but does not expand the use of fair value in any new circumstances. The standard clarifies that for items that are not actively traded, such as certain kinds of derivatives, fair value should reflect the price in a transaction with a market participant, including an adjustment for risk, not just the organization’s mark-to-market value. SFAS No. 157 also requires expanded disclosure of the effect on earnings for items measured using unobservable data. Under SFAS No. 157, fair value refers to the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability. In this standard, the FASB clarifies the principle that fair value should be based on the assumptions market participants would use when pricing the asset or liability. SFAS No. 157 is effective for fiscal years beginning after November 15, 2007. Earlier application is encouraged, provided that the reporting entity has not yet issued financial statements for that fiscal year, including any financial statements for an interim period within that fiscal year. The Foundation intends to adopt SFAS No. 157 as it applies to its fiscal year ending August 31, 2009 and is evaluating the impact. In February 2007, the FASB issued Statement No. 159, The Fair Value Option for Financial Assets and Financial Liabilities - Including an Amendment of FASB Statement 115. SFAS No. 159 permits entities to choose to measure certain financial instruments and other items at fair value. The objective is to improve financial reporting by providing entities with the opportunity to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions. SFAS No. 159 is effective for fiscal years beginning after November 15, 2007. The Foundation is currently evaluating whether to adopt SFAS No. 159 as it applies to its fiscal year ending August 31, 2009. In June 2006, the FASB issued FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes (FIN 48). FIN 48 requires that a tax position be recognized or derecognized based on a “more likely than not” threshold. This applies to positions taken or expected to be taken in a tax return. In December 2008, the FASB issued FASB Staff Position (FSP) FIN 48-3, Effective Date of FASB Interpretation No. 48 for Certain Nonpublic Enterprises. FSP FIN 48-3 permits an entity within its scope to defer the effective date of FASB Interpretation 48 (Interpretation 48), Accounting for Uncertainty in Income Taxes, to its annual financial statements for fiscal years beginning after December 15, 2008. The Foundation has elected to defer the application of Interpretation 48 for the year ending August 31, 2008. The Foundation evaluates its uncertain tax positions using the provisions of FASB Statement 5, Accounting for Contingencies. Accordingly, a loss contingency is recognized when it is probable that a liability has been incurred as of the date of the financial statements and the amount of the loss can be reasonably estimated. The amount recognized is subject to estimate and management judgment with respect to the likely outcome of each uncertain tax position. The amount that is ultimately sustained for an individual uncertain tax position or for all uncertain tax positions in the aggregate could differ from the amount recognized. The Foundation is evaluating the impact and does not believe its financial statements include any uncertain tax positions.

25
NOTE B–RESEARCH GRANTS At August 31, 2008 and 2007, the accompanying statement of financial position includes research grants aggregating $8,641,721 and $10,409,191, respectively, which are payable within one year. Research expense on the statement of activities is net of $2,451,783 and $432,497, representing return of prior year grants for terminations or refunds for the years ending August 31, 2008 and 2007, respectively. Research grants and awards disbursements total $15,508,006 and $14,444,464 for the years ended August 31, 2008 and 2007, respectively. In addition, the Foundation has unpaid conditional grants outstanding of $11,911,777 and $19,736,431 at August 31, 2008 and 2007, respectively, which are payable upon satisfaction of the underlying conditions and, therefore, they are not recorded in the statement of financial position. NOTE C–PLEDGES RECEIVABLE Pledges receivable, discounted to present value, are due to be collected as follows: 2008 2007 Within one year One to five years More than five years $3,253,947 1,807,772 370,000 $2,702,709 2,874,000 380,000 5,956,709 (259,780) 5,696,929 (213,000) $5,483,929 2. Capital Lease Obligation The Foundation leases certain equipment under an agreement classified as a capital lease. The equipment is included in furniture, equipment and leasehold improvements on the balance sheet and depreciation of the assets is included in depreciation expense. The remaining lease obligation of $37,121 is due in the year ended August 31, 2009. NOTE H–PENSION PLAN The Foundation has a defined contribution pension plan. Employees are eligible to participate in the plan upon hire, with full vesting upon one year of service. Contributions to this plan are 5% of the participating employees’ salaries. The Foundation’s contribution to the plan was approximately $336,000 and $269,000 for the years ended August 31, 2008 and 2007, respectively. NOTE I–TEMPORARILY RESTRICTED NET ASSETS Temporarily restricted net assets are available upon satisfying the following restrictions: 2008 2007 Purpose restrictions Research programs Education programs Time restrictions $3,660,476 1,296,694 463,869 $4,927,640 915,638 636,974

Financial Statements

$5,421,039 $6,480,252 NOTE J–NET ASSETS RELEASED FROM RESTRICTION For the years ended August 31, 2008 and 2007, net assets were released from donor restrictions by incurring expenses satisfying the restricted purposes specified by donors or the passage of time as follows: 2008 2007 Research programs Education programs Time restrictions $9,351,561 $4,949,056 2,016,788 226,116 169,045 – $11,537,394 NOTE K–RELATED PARTY TRANSACTIONS During the years ended August 31, 2008 and 2007, the Foundation held investment assets with an investment company. A Foundation trustee was employed as a Vice President of the company until July 17, 2008. All investments of the Foundation are held by this company and fees paid by the Foundation to the company were approximately $128,000 and $78,300 for the years ended August 31, 2008 and 2007, respectively. The company was selected by the Board of Trustees after review of other available options. The Foundation receives contributions from members of the Board of Trustees. For the years ended August 31, 2008 and 2007, respectively, members of the Board of Trustees contributed $178,548 and $127,678. Included in pledges receivable was $1,578,305 and $3,264,684 due from related parties for the years ended August 31, 2008 and 2007, respectively. The Foundation uses a website to process online contributions for special events. This website is affiliated with a member of the Foundation’s Board of Directors. The Foundation is charged a 6% processing fee on all transactions. For the year ended August 31, 2008 total fees paid were approximately $249,000. NOTE L–CONTINGENCIES The Foundation is subject to various claims and legal proceedings arising out of the ordinary course of business. Management believes the resolution of claims and pending litigation will not have a material effect, individually or in the aggregate, on the consolidated financial position of the Foundation. $5,175,172

5,431,719 Discounted to present value (at rates ranging from 2.17% to 7.00%) (148,988) Net present value Allowance for doubtful accounts Pledges receivable, net NOTE D–CHARITABLE REMAINDER TRUSTS 5,282,731 (87,000) $5,195,731

At August 31, 2008 and 2007, the Foundation has remainder interests in several irrevocable charitable remainder trusts. The present value of the Foundation’s future interests in these charitable remainder trusts, which amount to $311,920 and $341,872 at August 31, 2008 and 2007, respectively, have been recorded as charitable remainder trusts, in accordance with the terms of the trusts and are included in temporarily restricted net assets. The present value of the trusts was calculated using a discount rate of 5.8% at August 31, 2008 and 2007, respectively. Change in value of the charitable remainder trusts was $29,952 and $22,838 in 2008 and 2007, respectively. NOTE E–INVESTMENTS The fair value of investments at August 31, 2008 and 2007 consisted of the following: 2008 2007 Cash and cash equivalents Marketable securities Limited liability companies U.S. Treasury bonds Other Total investments $1,914,866 7,836,685 1,374,979 – – $2,118,006 6,401,086 1,155,795 3,971,135 262,649

$11,126,530 $13,908,671

NOTE F–FURNITURE, EQUIPMENT AND LEASEHOLD IMPROVEMENTS Furniture, equipment and leasehold improvements consisted of the following at August 31, 2008 and 2007: 2008 2007 Furniture and fixtures Equipment Computer equipment Leasehold improvements Less: accumulated depreciation Fixed assets, net $381,418 285,681 1,051,025 684,523 $595,529 285,681 2,157,717 684,523

2,402,647 3,723,450 (1,374,410) (2,430,589) $1,028,237 $1,292,861

Depreciation and amortization expense for the years ended August 31, 2008 and 2007 was $433,281 and $427,023, respectively. NOTE G–COMMITMENTS 1. Operating leases The Foundation leases office space for the National Office and Chapter offices in various cities throughout the country. These leases expire at various dates and have renewal options ranging from three to five years. The volunteer affiliate has no rent commitments. The leases provide for increases in future lease payments. The minimum annual rental commitments under operating leases are as follows: Year ending August 31, 2009 2010 2011 2012 2013 Thereafter Total $1,042,544 871,639 582,377 496,400 413,970 34,560 $3,441,490

Rent expense was approximately $1,226,000 and $1,149,000 for the years ended August 31, 2008 and 2007, respectively.

Friends of CCFA
We gratefully acknowledge the support of the donors who contribute to the Crohn’s & Colitis Foundation through the Combined Federal Campaign, State Employee campaigns, the United Way, and all other federated campaigns in the workplace.

The Crohn’s & Colitis Foundation extends its deepest regrets to any donor whose name may have been inadvertently omitted from this list.

27
INDIVIDUALS AND FOUNDATIONS Premier Donors $250,000 + Cathy & Peter Pappas, Sr. Irene and Peter Pappas, Jr. Elvin & Janet Price Ms. Michele Raphael Estate of Abraham Rich Estate of Judith Saphir Mrs. Ilene Schwartz Elaine & Alan Weiler Guardians $50,000 + Nina & David Fialkow Bruce & Dale Frankel Estate of James & Mary Franklin Senator Charles Fuchillo Diane & Barry Ganz Irwin and Joan Geduld Family Foundation The Gelber Foundation Lisa and Douglas Goldman Fund Richard and Rhoda Goldman Fund Elaine & Michael Stephen Goldstein Mr. Alan Grad Jill & Robert Hoberman Horwitz Family Memorial Foundation Mr. & Mrs. John Imbesi Mr. & Mrs. Jay and Dawn Johnson Jeffrey Justin Kassner Family Foundation Leo & Barbara Karas Zach & Jessica Kerr Karen & Richard Kleinman Jackie Tyree Kos & Al Kos Elizabeth Krulik Mr. Murray Kushner Mr. & Mrs. Tom Kuzma Mrs. Claire Levine Ms. Holly Lissner MacDonald Peterson Foundation Alma Lee Marshall David Maus Foundation Mc Ateer Memorial Golf Fund Michael and Rhonda McCarthy John P. McGovern Foundation Mr. & Mrs. Benson R. McLendon, Jr. Mrs. Elsie Miller Ted Moudis Caroline & Anthony Nastasi Mr. & Mrs. James A. Parrish, Jr. Ms. Betty J. Powers Mary & Bruce Rabiner Mrs. Violet G. Raum Mr. & Mrs. Donald Rechler Mitchell & Deborah Rechler Mrs. Shelley Redstone Dr. David M. Roseman The Scottish Rite Foundation of Missouri, Inc. Joel & Lauren Shapiro Louis & Emily Shapiro Sam & Gina Shapiro Kay & Richard Sherman Silicon Valley Community Foundation Senator Dean Skelos Mr. Lester Smith Estate of Anita Stauffer Mr. & Mrs. Steven Strasser Dr. & Mrs. Paul Tartel Mr. & Mrs. Van Van Auken Meredith Waldner Stern Stephen Waldner Mr. & Mrs. Holland Walsh Mr. Bruce Wasserstein Leon & Marysue Wechsler Stephen B. Wechsler Yahoo! Employee Foundation

Friends of CCFA

Roberta & Irwin Chafetz Arie and Ida Crown Memorial Ellen & Daniel Crown Jay and Ann Davis Richard Davis Mr. & Mrs. Lawrence Finkelstein Mr. & Mrs. Melvin Finkelstein Get Your Guts In Gear Mark & Diane Goldman Greenspun Family Foundation Mr. & Mrs. Brian Greenspun Mr. & Mrs. Daniel Greenspun Ms. Susan Greenspun Fine Mr. & Mrs. Leonard Litwin Mankoff Family Foundation Jeff & Staci Mankoff Ron & Joy Mankoff Barbara & Fred Miller Abby Modell Robin & Mitchell Modell Shelby & William Modell Lisa & James A. Pappas Cecile Patterson Suzanne & Irwin Rosenthal The Bruce and Cynthia Sherman Charitable Foundation, Inc. The William Stamps Farish Fund Daniel L. Stone Michelle & Howard Swarzman Michele & Steven Sweetwood Patrons $100,000 +

Anonymous Donor, Mid-America Chapter Anonymous Donor, Southwest Ohio Chapter Jane & Michael Axelrod The Jacob & Hilda Blaustein Foundation, Inc. Ethel Wilson Bowles and Robert Bowles Memorial Fund Benjamin G. Darnell Isabelle & Donald DiRenzo, Sr. Estate of David E. Drexler Estate of Gerald W. Dulkis The Samuel R. Dweck Foundation Mr. & Mrs. Maury Ettleson Joan Falk Lori and Howard Fensterman Mrs. Phyllis Frias Mr. & Mrs. Jeffrey Gale The Galen Family Foundation The Gillman Family - Shaldine, Richard, Marc, Sloane, Scott, & Andrea Monte & Rita Goldman Mr. & Mrs. Mark James Susan & Michael Kerr F.M. Kirby Foundation, Inc. Debbie & Jeffrey H. Margolis Arthur & Jayn Marshall Ms. Cari Marshall Mr. Todd Marshall Pamela & Edward S. Pantzer

Anonymous, Greater Washington D.C./ Virginia Chaper Anonymous, Illinois Carol Fisher Chapter Pauline Arama-Olsten & Stuart Olsten Mr. & Mrs. Bruce R. Behren Leo & Louise Benatar Nancy & Howard Brown Estate of Steven Colt Leon & Toby Cooperman Mr. & Mrs. Edgar M. Cullman, Sr. Elissa & Edgar M. Cullman, Jr. Rhondell & Glen Domilici Mr. Arthur J. Epstein The Fondren Foundation Gordon & Regina Ford Estate of Phillip Goos Mr. & Mrs. Steven L. Gringauz Mr. & Mrs. Jay and Dawn Johnson Koss Foundation, Inc. Mr. & Mrs. Michael Koss Mr. & Mrs. Ronald A. Krancer Seymour & Carol Levin Francine & Laurance Nagin Susan & Donald Newhouse Ms. Agnes Nixon Mr. & Mrs. Jerry Romanoff Mr. & Mrs. Gary Scharf Dr. & Mrs. Victor Scharf Marshall Sparberg, M.D. Linda Tallen & David Paul Kane Educational and Research Foundation The Wasie Foundation Mrs. Joan Wheeler The Wilbur May Foundation The Michael Yendick Foundation for Children Fellows $25,000 +

Anonymous, Houston Gulf Coast/South Texas Chapter Bonnie & Charles Alter Steven Bash Michele & Paul Berger Mr. & Mrs. Fred Berman Mrs. Irene Bloomstein Patrick & Greggory Burk Mrs. Elizabeth Calhoun The Community Foundation For The National Capital Region Mr. & Mrs. Joel E. Cutler Mrs. Vera Deutsch Mrs. Sandra M. Edgerley The Lester M. & Sally Entin Foundation Mr. & Mrs. Stephan Feder

Sponsors

$15,000 +

Mr. & Mrs. Murray Beer Greg Berk Estate of Adele Blank Mr. & Mrs. Michael Brown Mr. & Mrs. John Burns Kenneth Carmel Mr. Frank Casal Mitzi Cloud The Cowles Charitable Trust Mr. & Mrs. Theodore Cutler Daniell Family Foundation Inc. Diamondston Foundation, Inc. Brian Donaghy Lester M. & Sally Entin Foundation Art & Marcy Falcone James Fitch Foundation For Research of Pediatric Colitis Futures & Options for Kids, Inc. Lisa & Tony Gerrato Alex Getelman The Giant Eagle Foundation Gary Goldman Mr. & Mrs. Robert Goldstein Mr. & Dr. Joe Gugger Ms. Hanna Hombordy Mr. & Mrs. Donald Jacklin Estate of Kathryn Ann Jacklin Allen & Dana Jacobson Ms. Audrey S. Katz Mrs. Lenora Klein Knoxville Christian Community Foundation The Kupferberg Foundation Mr. & Mrs. Don LaRocca The Lance Robert McLendon Foundation Eve Milstein Elyse & Michael Newhouse New York Yankees Foundation Mr. & Mrs. S. Christian Nielsen, III Mr. & Mrs. Ira Pittelman The Herman T. & Phenie R. Pott Foundation Bruce & Mary Rabiner Mr. Robert Raphael Mr. & Mrs. Jan Rask Mr. & Mrs. Sumner Redstone Samantha & David Ripka Dr. & Mrs. James Rooney Ellen J. Scherl, M.D. Mr. & Mrs. Malcolm Schwartz The Sidgmore Family Foundation Dr. Harry Sobel Tammi & Mark Stempel Mr. & Mrs. David Taffet Mr. & Mrs. Arthur Tauber The Tudor Foundation Inc. J. Robert and Diane Ward Anthony Westrick The Wishlist Foundation Carol & Joseph Wolfer Benefactors $10,000 +

Ms. Amy Abrams Albert and Margaret Alkek Foundation

Ms. Angela Anton Arthur Backall Mr. & Mrs. Joel Barnett Mr. Edward M. Bernstein Beta Sigma Phi Bogen Family Charitable Trust Boston Foundation Julie & Paul Brandes Dr. Martha D. Brown Kim Calvo Lisa Chanoff Mr. Stanley I. Chera Mr. & Mrs. Dennis Ciccone Diane & Peter Cosentino Mr. & Mrs. Percy Creuzot Estate of Doris Curtis Scott & Kathleen Dalecio Kimberly DeLape Alan & Lorie Delk Mr. & Mrs. Steven Drooker Eastern Bank Charitable Foundation Larry Elins J. A. & Isabel M. Elkins Foundation Feil Family Foundation Sally & Steve Feldberg Mr. Jerry D. Fields Mark & Randi Fisher Mrs. Patricia D. Forbes Mr. & Mrs. Richard Frankel Mr. Jay Furman & Dr. Gail Furman Morris & Gertrude Furman Foundation The Berenice Gates Hopper Family Fund Mr. Alex Getelman Giarla & Michelson Charitable Foundation Gilbert Family Foundation Mr. Howard Gleicher Mr. Les Goodstein Mr. & Mrs. Jim Gordon Reuben & Mollie Gordon Foundation Stone Gossard The Greater Cincinnati Foundation Grebow Family Foundation The George & Mary Josephine Hamman Foundation Robert & Mary Sue Hawk Jill Heller Hellman Family Foundation Janet & Arthur Hershaft David Horing Ms. Helene Houle Mr. & Mrs. Michael Hubbe Estate of Linda Jellenik Mr. & Mrs. Howard Jessen Mr. & Ms. Louis Kaitz The Kaplen Foundation SK Children’s Charities Mark & Dawne Kaufman The Louis J. and June E. Kay Foundation Kirkland & Ellis Foundation Mr. & Mrs. Richard Klapman Mr. & Mrs. Seth A. Klarman Mindy Kristel-Wolinsky S&C Kushner Family Foundation Karen & William Lauder The Lehman Brothers Foundation

Ms. Beatrice Lempel Saul & Eleanor Lerner Foundation Mr. Al Loverde Mr. Thomas Levy Lucinda Loya Lori Lupini Mr. & Mrs. Harold Matzner Andrew & Lydia Mays McAteer Family Trust Mike McCready & Ashley O’Connor Joan & Peter McKee Jason & Amy McLevaine Mr. Shaun Meehan Ms. Katherine Merage Mr. & Mrs. Wallace D. Mersereau Mr. Thomas Messina Mr. A. Chris Meyer, Jr. Middle Tennessee Electric Membership Corporation Diane & Stanley Miller Mills Family Charitable Foundation Mrs. Ioanna Moore The Mr. 59 Foundation Laura Ellen & Robert Muglia Mr. John Nasseff & Ms. Helene Houle Albert & Angela Nassi Ron Petrich Mr. Kevin Plank Raymond Quartararo Dr. & Mrs. James M. Rabb Mrs. Ashley Reifler Randi & Dennis Riese Mr. & Mrs. Joseph Rosen Mr. David S. Rosenberg Iris & Walter Rubenstein Mr. & Ms. Mark H. Rubin Mr. Michael G. Rubin Mr. Morton Ruderman The San Diego Foundation Myron Feinberg Endowment Fund Jeffrey & Nancy Schondorf Mr. & Mrs. William Schulder Donna & Marvin Schwartz Estate of Herman and Blanche Selwyn Mr. & Mrs. Mark Seruya Mrs. Mary Sexton Lester & Edna Shapiro Family Foundation Mr. & Mrs. Steven M. Shapiro The Harvey Silverman Foundation, Inc The Elwood & Carol Simon Family Foundation The Sidney, Milton and Leoma Simon Foundation Warren & Roberta Sirzyk Mr. & Mrs. Michael Sobecki Dr. & Mrs. Max A. Sobel The Lawrence & Lillian Solomon Fund, Inc. Mr. Randy Stilley Mr. Edward Streim Valerie Swarbrick Carmella & Peter Tully Edward & Scott Turen A. Raymond Tye Mr. David M. Underwood Caron & Michael Vanaria James & Kathryn Vaughan

29
Wal-Mart Foundation The Walsh Foundation The Jamison Williams Foundation Irma & Sidney Winoker Lois Robbins Zaro Associates $5,000 + Clarcor Foundation Mr. & Mrs. John Cleary Mr. & Mrs. Jerry Cohen Milton L. Cohen & Norma M. Cohen Family Foundation Inc. Mr. & Mrs. Stanley L. Cohen Coldwell Banker Residential Brokerage Community Foundation Mr. & Mrs. David Colman Sally Connolly Milton Cooper Foundation, Inc. Dr. Richard Corcoran Peter Cosentino Mr. & Mrs. Howard Cowan Gerald Croan Mr. Rod Crosby Cubs Care, a fund of the McCormick Tribune Foundation Helen R. Cyker Mark F. Dalton Daniels Family Foundation Mr. & Mrs. Sean Dany The Davenport-Hatch Foundation Benjamin & Frances David Foundation Mr. & Mrs. Dennis D. Dorman Dorskind Family Foundation Mr. & Mrs. Robert Dubin Mr. & Mrs. Edward Dunlap The Dyson Foundation The Elmezzi Private Foundation Ruth Epstein Schuler Foundation Juliet Fadely David & Ruth Falkenstein The Fan Fox and Leslie R. Samuels Foundation Inc. Fant Foundation Mrs. Shelley Fehrenbach Dr. Allan Feingold Ms. Judy Felsenthal Carl Ferraro Mr. Joe Feshbach Ms. Michelle Filteau Mr. & Mrs. Richard Fineburg Susan and Leonard Feinstein Family Foundation Mr. Bruce J. Fingeret The Herman & Jerry Finkelstein Foundation Ms. Harriet M. Finn Mr. & Mrs. Michael Francis Mr. and Mrs. Michael Francisco Virginia Friedhofer Charitable Trust Friedman Supporting Foundation Philip M. Friedmann Mrs. Pauline Frohlick Mr. & Mrs. Nathan Froot The G&A Foundation Inc. Ms. Melissa Gallagher David Gantos Mr. & Mrs. Andrew S. Garb The Eliot J. Garber Foundation Inc. Mr. Michael Genatt Allison Gerber Mr. Richard Geswell Mr. & Mrs. Albert Gherlone Mr. and Mrs. Ned Gill, III Brandon Gillman Mr. Laurence T. Ginsberg Glaser Progress Foundation Mr. & Mrs. Robert Glass Mr. & Mrs. Morton Gleicher Mr. & Mrs. Joel Glickman Robert Glickman, M.D. Ms. Stana Gnatovich Mrs. Judy Gold Earl & Suzanne Goldberg Samuel Goldberg & Sons Foundation Mr. & Mrs. Jonathan Goldman Carol H. Goldsmith & Aaron Goldsmith Steve and Katie Goodman Suzanne H. Gorab Mr. & Ms. Gerald T. Goss Mr. & Mrs. Warren Grant Pamela Graven Ms. Susan Zises Green Mr. & Mrs. Alan Greenberg Lewis Greenwood Foundation Mrs. Bonnie Gregge Linda & Donald Gross Mr. Ira Gross Mr. & Mrs. Michael Gross Mrs. Ellen Grossman GUESS? Foundation Staci Gura Mrs. Jill Haber Mr. Ed Haiken Halpryn Family Foundation Inc. Estate of Richard Hauser Heller Bros Foundation Mr. Dan Heller Mrs. Ruth Hendel Michelle & Scott Herbert Mr. & Mrs. Robert Hernandez Betty & Rodger Hess Ms. Margaret Hively Tim Holiner Ms. Daisey Holmes Douglas Horlick The Ralph and Genevieve B. Horween Foundation Mr. & Mrs. G. B. Howard, IV Mr. & Mrs. Henry Hoyt, Jr. Mr. Richard Hunt Mr. & Mrs. Joseph J. Israel June Jacobs Mr. and Mrs. Robert Jasper Mr. Joe Johnson Mr. & Mrs. Paul T. Jones Mr. Peter Joseph Norman & Lisa Judah Alyne & Abbey Kaplan Ms. Jane Kapp Samuel and Rebecca Kardon Foundation Karp Family Foundation Ms. Martha Karsh Rebecca Keith Mr. & Mrs. Michael Kempner Mr. & Mrs. Eugene Kestenbaum The David Kimmel Foundation Ms. Carrie Kirk Ms. Marjorie Klayman

Friends of CCFA

Anonymous, Fairfield/Westchester Chapter Anonymous, Greater Los Angeles Chapter Anonymous, Greater New York Chapter Abrams Foundation, Inc. Mr. & Mrs. Jim Abrams Stanford & Joan Alexander The Alkek and Williams Foundation Dr. Sharon Alloy American Dream Foundation Inc. Fred C. and Katherine B. Andersen Foundation Ms. Rhea Anderson The Annenberg Foundation The Applebaum Foundation Inc. Ms. Debbie Attanasio Meg & Jay Axelrod Mr. & Mrs. Arthur Baird David & Gwen Baker Mr. & Mrs. Ralph Barnett Mrs. Linda C. Barry Judy & Joel Bauer, M.D. Mr. Eric D. Becker Mrs. Janine Behrman Ferdinand E. Belga Mr. Ward Bennett Dr. & Mrs. Michael Berger David & Betty Berkman Mr. Jeffrey Berkowitz Mr. Xerxes Bhote Angela Biggar Mr. & Mrs. Christopher Billmeyer Bishop Family Foundation Mr. & Mrs. Howard Blatt Michael & Nina Blechman Mr. Gerald Block Mr. & Mrs. Fred Blume Employees Community Fund of Boeing St. Louis David & Georgia Boutwell The Braeside Foundation Mrs. Judy Briskin Mr. Joshua Broder The Brooks Family Foundation Dr. and Mrs. David Brown Mrs. Eunice Brown Mr. & Mrs. John Brown Mr. & Mrs. Andrew Brucker Mr. Craig Caffarelli Mr. Frank Califano Cammarata Family Foundation Mr. & Mrs. Daniel D. Cantor Mr. Michael Cappelli The Caring Foundation Eula Carlos Foundation, Inc. Paul Casey & Family Cynthia Cassandro, R.N., B.S.N. Paul & Ruth Chosid Mr. Lance Chudnow

The Harry Kletter Family Louis and Rose Klosk Fund Knell Family Foundation Knez Family Charitable Foundation Cheryl Knippenberg Steve & Eydie Koonin Mr. & Mrs. Gerald Korde Mr. Robert S. Korff Mrs. Amy Kovac Mr. Richard Kuci Steve & Cathy Kuranoff Broh & Tracy Landsman Corinne Langer The Lauder Foundation Ms. Helen H. Lee Estate of Bernard Leeb Mr. & Mrs. Eric & Liz Lefkofsky Legg Mason Charitable Foundation Mr. Stew Leonard Ms. Dorothy D. Levey Mr. & Mrs. Abner Levine Mr. Jeffrey Libert & Ms. Martha Brown Mr. Michael Liman Mr. & Mrs. Martin Lindenfeld Dorina Link Maurice Lipnick Mr. & Mrs. Barry H. Lippman Mr. Louis J. Lombardi Mr. Sheldon Lustigman Dr. & Mrs. Mitchell Lynn Mr. & Mrs. Russell Maddox Madison Charitable Foundation, Inc. Mr. & Dr. Brian Maier Ms. Rochelle Maize Mr. & Mrs. Samuel B. Marcus Mr. & Mrs. William M. Marcus Kate & Joel Margolese Erica Marieb, Ph.D. Dr. & Mrs. Bradley Marsh James G. Martin Memorial Trust Sharla Martinez Mrs. Cynthia Marx Marx-Better Foundation The Lester & Grace Maslow Foundation Inc. Maxim Charitable Foundation Mary & Michael McDonough James & Swan McKnight Ari Meisel Dr. & Mrs. Samuel Melamed Ms. Ellen Michelson Mrs. Debra Michiels Joshua and Pamela Miller Family Gift Fund Laura Miller James Mills Mr. & Mrs. Arthur Modell Ms. Susan Molasky Mr. & Ms. Hernando Mora Mr. J. Roger Morrison Moss Foundation, Inc. Philip S. Muller Mrs. Alice Muskovitz Mr. Alan Nadler Namoff Family Fund Newell Foundation Bob & Barb Nieder

The William F. O’Connor Foundation The Orchard Farm Foundation Ortega Foundation Kathryn May Paben Family Charity Trust Greg & Janet Parker Kathleen & James L. Patton, Jr. Susan Peck Wayne & Christine Perry Ms. Joyce Persky Gary & Jill Podell J. Neal & Martha Purcell Quest Diagnostics Foundation, Inc Mr. & Mrs. Martin J. Rabinowitz Jan Rask Ms. Karen Rasmussen David & Cecelia Ratcliffe Milton R. Ratner Foundation Mr. & Mrs. Robert Reiner Rich Foundation, Inc. Ms. Rosalyn C. Richman Dr. Marcia Robbins-Wilf Ms. Jill Roberts Mr. & Mrs. Mitchell Roberts Mr. Philip Roberts & Ms. Alison Nesmith Mr. Richard I. Romanoff Dr. Jose Roque, M.D. Mr. & Mrs. Hal Rosenbluth Ross Family Fund Renee & Edward Ross Foundation Edwin & Louise Rothberg Mr. & Mrs. Stuart Rothenberg Mr. Eric Rothfeld Rothman Family Foundation Mr. & Mrs. Marc Rowan Mr. Tim Russert Mr. & Mrs. Jerry Ruthman Mr. Edward G. Ryan Mrs. Selma Ryave Mr. Kenneth Sacks Dr. & Mrs. Don Safer Sampson Family Charitable Foundation Mr. & Mrs. Norton Sarnoff Dr. Howard Scalone Tina Hoffman & Geoff Schechter Mrs. Jane K. Scheinfeld Charles & Mildred Schnurmacher Foundation Mr. & Mrs. Glenn G. Schreiner Dr. & Mrs. Ron and Susan Schwartz Mr. Scott Schweighauser Mr. Jeremy Sclar Anita Shapiro Ellen & Steve Shapiro Mr. Harry S. Shapiro Mr. & Mrs. Jerry Shapiro Mr. Ed Shea George L. Shields Foundation, Inc. Ms. Michelle Shopenn Mrs. Barbara Shurgin Mr. Mace Siegel Judy A. Sigal Mr. & Mrs. Jeff Silverstein Marc A. Silverstein, M.D. Mr. & Mrs. David Simon Mr. & Mrs. Gary Sinderbrand

Mrs. Karen S. Singer Mr. & Mrs. Alfred Slifka Mr. & Mrs. Reed Slogoff Robbyn Sockolow, M.D. Mr. & Mrs. Gary N. Solomon Mr. & Mrs. Theodore G. Solomon Mr. & Mrs. Martin Spector Terry Gillespie & John Stanton Ms. Nancy G. Steir Burton & Barbara Stern Mr. Frederick Stow Mr. & Mrs. Herbert Strauss The Rose & Bernard Strauss Foundation Inc. Stronge Family Foundation Mr. Greg Sulger Mr. Sidney Swartz Mrs. Mary S. Sweeney Mr. Evan Tannor TCF Foundation Mr. & Mrs. Vincent Tese The Thompson Foundation Mr. & Mrs. Hall Thompson Mr. & Mrs. A. Richard Tischler Scott & Tina Tracy Mr. & Mrs. Thomas Tuft Mrs. Patricia B. Turen Ms. Martha Turner Marshall & Terri Turner Mr. & Mrs. Thomas B. Tyree, Jr. William F. & Barbara Tyree Mr. & Mrs. Bruce Tyson Mr. & Mrs. Dick Valente Victory Hope Foundation Meredith Vieira Mr. Marc Vigod Mr. John Vissicchio Vitalogy Health Foundation Stephen Volk Mr. & Mrs. Robert Wachstein Mr. & Mrs. Gordon Waldorf Mr. & Mrs. John Walsh Weil, Gotshal & Manges Foundation Inc. Mr. & Mrs. Jim H. Weiss, Sr. Wells Fargo Community Support Campaign Mr. Bruce Wessel Jeffrey & Cynthia Wiesenfeld Mr. & Mrs. Robert D. Wildstein Mr. Michael C. Wilkins Nell Williams Family Foundation Barry D. Winston, M.D. Mr. Ronald Winston Col. & Mrs. Charles H. Wittrock The Frances Wood Wilson Foundation, Inc. Ms. Tania Wood Wyse Family Foundation Mr. & Ms. Paul Zagaria Mrs. Lynn Zimmer Mr. Lawrence Zimmerman Mrs. Cathy W. Zises

31
CORPORATIONS Premier Donors $250,000 + Sponsors $15,000 + 386 PAS Partners LLC Adidas Aragon Associated Pipe Line Contracters Beacon Hill Staffing Group Blank Rome LLP Blue Cross Blue Shield of Louisiana Camp Magic, Inc. Cushman & Wakefield, Inc. Dorland Corporation Edmunds & Associates Emageon ESPN, Inc. Falcone Group, LLC Futures & Options For Kids, Inc. Gibraltar Bank Global Impact Grampy’s Charity Open HFTP Front Range Chapter JustGive The Kamson Corporation Kirkland & Ellis, LLP Land Resource Companies, LLC Lane Office Furniture, Inc. Los Angeles Lakers, Inc. MedThink Communications National Distributing Company Inc. New Balance Athletic Shoe New York Islanders Hockey Club New York Knights of the Grip The News Corporation Memorial Hermann Hospital System Perry Ellis International, Inc. Pico Holding, Inc. Postgraduate Institute For Medicine Rorer Asset Management, LLC Smashbox Cosmetics State Farm Insurance Companies Ted Moudis Associates Thomson Reuters Timberland Company Under Armour Athletic Apparel Valley National Bank VF Services, Inc. Vornado Realty Trust We Care In IBD The West Penn Allegheny Health System Western Oil Company, Inc. Westgate Capital Management Benefactors $10,000 + Capital Source Charitybuzz Chubb Federal Insurance Company CIBC World Markets Corp. Cleveland Clinic Health System Commerce Bank Community Progress Committee, Inc. Cordis Corporation Costco Wholesale EDS Employee’s Community Fund of the Boeing Company Everlast Worldwide Inc. Excellent Home Care Services LLC FC Management Fifth Avenue of LI Realty Assoc. Fisher Brothers Five Star Refrigeration, A/C & Heating LLC Frank Crystal & Company Gotham Technology Group Hanesbrand, Inc. Heller Ehrman, LLP Hollister Incorporated Illinois Council of Voluntary Health Agencies Indianapolis Endoscopy Center JPB Enterprises Kelley Shootout Golf Scramble Kennedy Funding K’NEX Industries, Inc. Lehman Brothers Lupini Construction M & R Management Co., Inc. Macsteel International USA Corp. Maddox, Hargett & Caruso Major League Baseball MDA Contracting Mednikow Jewelers Middle Tennessee Electric Membership Corporation Miller Properties MONY Life Insurance Company N.A.U.S. Charity Fund, Inc. Newmark & Company Real Estate NFL Charities Northeast Private Client Group Nova Southeastern University Oak Ridge Investments Olsten Corporation Pepper Hamilton, LLP Plaza Construction Reebok International Ltd. Sacramento Area Miata Owners Association (SAMOA) Sangari USA, LLC Sills Cummis & Gross P.C. Six G’s Venture SL Green Realty Corp Southern Company The Oregon Clinic The TriZetto Group, Inc. Turner Construction Company Vandenberg Communications Viacom International, Inc. Winick Realty Group Yum! International

Friends of CCFA

Abbott Centocor Ortho Biotech Inc. John Wiley & Sons, Inc. Modell’s Sporting Goods P.J. Mechanical Corp Procter & Gamble Pharmaceuticals Shire plc UCB Patrons $100,000 +

Abrams, Fensterman, Fensterman, Flowers, Greenberg & Eisman, LLP Advanced Health Media Fleet Honorarium Account Century Club Charities ConvaTec Elan Embryon Rechler Equity Partners Salix Pharmaceuticals, Inc. TJX Companies Guardians $50,000 +

Atlanta Attachment Co. Axcan Pharma US Koss Corporation McNeil Consumer Healthcare Millennium Pharmaceuticals, a wholly-owned subsidiary of Takeda Pharmaceutical Company Navellier & Associates, Inc. Otsuka America Pharmaceutical, Inc. PGA Tour, Inc. PNC Wealth Management Renegade Swish, LLC Signature Bank The State of New York Wachovia Securities Wolf Popper LLP Fellows $25,000 +

AFA Protective Systems, Inc. Alaven Pharmaceutical, LLC Bank of America Jr. Beta Club of Louisiana Bristol-Myers Squibb Company Capstone Asset Management Company Dietz & Watson Galashiels Fund Limited IBM Employee Services Center N B Family LTD Partnership LP Nastasi & Associates Inc. OMDUSA, Inc. Prometheus Laboratories, Inc. Shapiro Capital Management Co., Inc. Ximed Digestive Disease Research Center

AFD Contract Furniture, Inc. Agron, Inc. AIG All Metals Industries Allstate Giving Campaign American Securities Capital Partners, LLC America’s Charities The Bank of New York Mellon Bilzin Sumberg Baena Price & Axelrod L.L.P. Bloomingdale’s Blue Cross Blue Shield of MA

Associates

$5,000 +

Anonymous, Carolinas Chapter Abington Reldan Metals LLC Active Screw & Fastener Advantage Title Agency Inc. Air Perfect Testing Akerman Senterfitt Alcatel-Lucent Allied Group Holdings, Inc. Allied NA Ins B’kge of NY, LLC AmSurg Corp. AmTrust Bank Arapahoe Gastroenterology P.C. Argonne National Lab Armitron/E-Gluck Corporation Arris Ashlar Mechanical Corp. Asia Five Eight LLC AutoZone Barnes & Noble, Inc. Baron Capital, Inc. Baylor College of Medicine BDO Seidman LLP Bell Sports Inc. Biogen Idec Blackstone Administrative Services Partnership, LP BNY Mellon Wealth Management Boston Herald Bovis Lend Lease Interiors, Inc. Brooklyn Carpet Exchange, Inc. Burklund Distributors, Inc. CAMAC International Corporation The Cambridge Towel Corporation Campbell Bohn Killin Brittan & Ray, LLC Capital Process Servers CBS Corporation Cebert Pharmaceuticals CenterPoint Energy Chaplin’s Automotive Group Children’s Health Care Associates, Inc. The Children’s Hospital of Philadelphia GI Dept. The Clarks Companies, NA Colon & Rectal Surgery Associates, LTD Comerica Bank-Western Market ConocoPhillips Cosentino Brothers Development LLC DeMartino Construction Digestive Health Mgmt, LLC Dodge Communication, Inc. Doody Mechanical Durst Organization East Coast Appraisers Eclipse Berry Farms, LLC Egan Insurance, Inc./Chubb Insurance Co. El Gaucho EMC Corporation Epic Systems Corporation Epiq Systems Erie General Electric Federal Credit Union Euro RSCG Life Chelsea E-Z-EM, Inc. Fabian Couture Group International, Inc.

First Commercial Bank First Trust Fore Winds Management, LLC Frederick Goldman Inc. Fuller & O’Brien Insurance Gastrointestinal Associates GEM Realty Capital, Inc. GI Pathology PLLC Give With Liberty Given Imaging, Inc. Good, Swartz, Brown & Berns, LLP Greenberg Traurig, P.A. Grossman and Roth, P.A. Grosvenor Capital Management HealthPartners Hermann Hospital Howard Hanna Real Estate Inovera Bioscience, Inc. INTECH Construction, Inc. InterContinental Hotels Group Invemed Associates LLC Janover Rubinroit LLC Jolie Toi/Sunny Haik Jones Day Jones Lang LaSalle Americas Joseph Finn Company, Inc. K.Swiss KeyBank National Association Trust Division Keystone Electronics Corp. Kiwanis Club of Patchogue KNG Construction Co., Inc. Lewitt, Hackman, Shapiro, Marshall and Harlan Loeb & Loeb M G Engineering, PC M J Soffe Co. Magid Glove and Safety Manufacturing Co. LLC Marlboro Footworks Ltd. Marriott International, Inc. McMaster-Carr Supply Company Medical Mutual of Ohio Medica-rents MeetingAdvice, LLC Memorial Healthcare Meridian Capital Group, LLC MetroPCS Michiana Gastroenterology, Inc. Morgan Stanley Trust, N.A. Morton’s National Basketball Association National Chef Supply Warehouse Network For Good New Jersey Devils New Jersey Nets The New York Community Trust The New York Mets Noble Drilling Corporation Oceaneering International, Inc. Olympus America Inc. Option Care Origlio Beverage Papé Material Handling Park National Bank

Patrolmen’s Benevolent Association of the City of NY, Inc. Penava Mechanical Corp. Personal Benefit Services Group, Inc. Pfizer Inc. Pharmaceutical Research and Manufacturers of America Philadelphia Stock Exchange Port of Houston Authority of Harris County Posternak Blankstein & Lund LLP PricewaterhouseCoopers LLP Progressive Proskauer Rose LLP Quiet Technology Aerospace Redhawk Engineering Inc. Rocky Mountain Gastroenterology Assoc., PLLC Rodman Publishing Corp. Royal Properties, Inc. Russell Corporation Russell Investment Group S.N. Tannor, Inc. Sedano’s Supermarkets Seminole Tribe of Florida Serono, Inc. Sheridan Healthcare Sigma Tau Pharmaceuticals, Inc. Skechers U.S.A., Inc. South Denver Gastroenterolgy Southeast Valley Babe Ruth Spicy Pickle Franchising, Inc. Sports Authority SSM Design LLP Starbucks Coffee Company Stark Carpet Stat Fire Suppressions Inc. Stearns Weaver Miller Weissler Alhadeff & Sitterson, P.A. Stone Tower Operating LP Structure Tone Inc. Suram Trading Corporation Sutter Home Winery Synovus Financial Corporation TCD Services, LLC Techlab, Inc. Thomas Jefferson University Hospital Tiger Capital Group LLC Tishman Speyer Tootsies, Inc. Top Banana LLC Transocean Offshore Deepwater Drilling Inc. Trigran Investments Trimark Turner Broadcasting System, Inc. UBS AG United Parcel Service UPMC Vanderbilt University Medical Center Variety of Georgia Verizon Warrior Roofing Manufacturing, Inc. Whitford Corporation Whitney National Bank Whole Foods Market Yale Mortgage Corp.

33
President’s Corporate Circle

President’s Corporate Circle
We are proud to acknowledge the members of the President’s Corporate Circle. These dedicated corporate leaders provide significant grants to the Foundation. They are committed to being our partners in progress, and have made possible many of the research and education programs discussed in this annual report. Abbott Axcan Pharma US Centocor Ortho Biotech Inc. Elan McNeil Consumer Healthcare Millennium Pharmaceuticals,
a wholly-owned subsidiary of Takeda Pharmaceutical Company

Otsuka America Pharmaceutical, Inc. Procter & Gamble Pharmaceuticals Salix Pharmaceuticals, Inc. Shire plc

Founders Society
Members of the Founders Society give a precious gift to everyone who has Crohn’s disease or ulcerative colitis: the promise that future generations will be spared the pain of these diseases. The Society honors those who strengthen the vision and commitment of our founders by including the Foundation in their will or estate plans. Founders Society Members provide for a healthy tomorrow in a variety of ways, such as making a bequest by inclusion of the Foundation in a will, charitable gift annuities, trusts, retirement plan gifts, and insurance policy gifts. The above is a limited sampling of how a legacy to benefit the Foundation may be accomplished. For more information, please visit our web site at www.ccfa.org/ plannedgiving or contact the Planned Giving Department at [email protected] or 800-932-2423. Please discuss with your attorney the means most appropriate for you. The Crohn’s & Colitis Foundation’s general counsel would also be happy to discuss with your attorney how best to accommodate your wishes. The Crohn’s & Colitis Foundation gratefully acknowledges the foresight, generosity, and commitment of our Founders Society Members:
Marie Alexander Estate of Marcia Altman Isabel Anderson Margaret Ashburn Trust Gloria Aucott Lucielle Bach Sara Backer Lois Bailey Lois Baker Nancy Baker Ira Bakst Kevin Barnes Elizabeth Basshaw Lois Battilana Raymond Battilana Mary Benton Estate of Julius Berkowitz Mary Berry Estate of Adele Blank Stephen Blank Tim Blank Estate of Dorothy Bliley Dave Blood Susan Borzenski Bryce Breitenstein Jill Brenneman Robert Brine Estate of Curtis Brown Patricia Brown Dona Browne Rona Budovitch Estate of Charles P. Bukowski Estate of Sidney Bull Lander Burr Rona Caplan Estate of Patricia Carney Jennifer Christensen Estate of Steven Colt Ruth Colten Phil Conley Michelle Covington Laura Cridlebaugh Betsy Culberson Phil Culberson Estate of Doris Curtis John Dayton Estate of Marie De Barbieri Vera Deutsch

35
Carol Dirks Mary DiSanti Estate of David E. Drexler Estate of Anna Druck Estate of Gerald W. Dulkis Kenneth Dunst Georgette Edkins Estate of Elizabeth Erasmus Mary Jane Evans Estate of Carol Rosenthal Ezring Estate of Myron Feinberg Karen Findora Alan Finn Carmen Fiorelli Estate of Ruth Fleisher William Frankenstein Estate of James Franklin Estate of Mary Franklin Johanna Frerichs Michelle Friedman Brenda Fudell Estate of Ruth Furman Estate of Jules Furth Estate of Catherine Gadomski Arlene Galbert Robert Garman Estate Of Charles Geist Annette Gilman Leonard Gilman Estate Of Harry Gold Deborah P. Goldberg Estate of Henrietta Goldberg Diane Goldfarb Donald Goldfarb Estate of Phillip Goos Mona Gordon Randi Gordon Miriam Gottlieb Estate Of Marion Gould Marcia Greenburg Estate of Clarence Gregory Toby Greene Lorri Greif Estate of Robert Grier Fanny Gruszecki Lillian Guy Bruce Hartzmark Judy Hauser Estate of Richard Hauser Bob Hawk Mary Sue Hawk Daniel Hawkins Michelle Henderson Estate of Frances M. Henry Clifford Hill Deanne Hill Herbert and Bonita Hirsch Hanna Hombordy Nancy Homeyer William Homeyer Gerald Honl Sandra Honl Estate of Kathryn Ann Jacklin Estate of Linda Jellenik Sharon Kahn Estate of Sylvia Kaplan Audrey Katz Mark Kaufman Dawne Kaufman June Kay Louis Kay Milicent Kellner Rita Kendall Eric Landau Renee Landau Beth Ann Landow-King Gloria Langos Patricia LaPedus Don LaRocca Karen LaRocca Louis Lauer Estate of Bernard Leeb Estate of Pauline Leibow Irma Leon Arthur Levine Judith Ludwig Levine Ronald Levy Michael Libys David Linemeyer Lucia Loding Adeline Luckman Juanita Ludke Harvey Luterman Estate of John Lynch Rusty Maddox Estate of Sylvia Malawsky Marc Marasco Margaret Marasco Edna Marcus Estate of Frank and Alma Lee Marshall Thomas Martin Carolyn Martin Constance L. Martin Nancy McNabb Henry Meyer Shelby Modell William Modell Cynthia Monter John Monter Noel Moore J. Roger Morrison Martha Morrison Pattie Moxham-Fisher Charles Munsey Barb Nieder Bob Nieder Agnes Nixon Steven Pantos Renee Parente Faye Parham Eleanore Patterson Santos Perez Oscar Peterson Estate of George J. Pierson Kathryn Pizza Maurice Plough Christine Pollock Mark C. Pope, III Estate of Rufus Porter Rex Rathbun Estate of Mary Ellen Reedy Estate of Abraham Rich Rosalyn Richman Carol Roberts Seymour Roberts Robin Roger Estate of Burt Rosenberg Mona Rosenberg Irwin Rosenthal Suzanne Rosenthal R. Warren Ross Arnold Rudoff Carol Rudoff Paul Russell Selma Ryave The Judith Saphir Research Fund Dr. Richard Saphir Roberta Schecter Bruce Schmitt Shirley Schreiber Dr. Ronald Schwartz Susan Schwartz Estate of Blanche Selwyn Estate of Herman Selwyn Carol Sexton Robert Sexton Roslyn Sher Judy Sigal Nettie R. Silverman George Smyth Sheldon Sokol Seymour Sperling John Spiecker Estate of Anita Stauffer Sylvia Steinbrock Estate of Joseph Sujansky Estate of Ellen M. Sullivan Beverly Taubel Eugene Taubel Jane Thomas Julie Townsend Felicia Traub Michael Tronzo Jeffery Tupper Rosemarie Van Ingen Jane Vandermeer Lawrence Vandervoorn Vivian Vandor Salvatore Varveri James Vaughan Kathryn Vaughan Estate of Adele Verkman Helene Victor Sara Jane Victor Jeffrey Ward Rene Warren Joseph Weisel Arie Weissman Estate of Evelyn Westberg Ray Whitaker Nancy Wiltgen Linda Windsor John Wine Charles Yochim Phoebe Yochim

Founder’s Society

Our Chapters
ALABAMA Alabama/Northwest Florida Chapter 244 Goodwin Crest Drive, Suite 120 Birmingham, AL 35209-3711 Phone: (205) 941-9900 Fax: (205) 941-1411 Email Address: [email protected] ARIZONA Southwest Chapter 8098 Via De Negocio, Suite 201 Scottsdale, AZ 85258 Phone: (480) 246-3676 Fax: (480) 246-3679 Email Address: [email protected] CALIFORNIA Greater Los Angeles Chapter 1640 South Sepulveda Blvd., Suite 214 Los Angeles, CA 90025 Phone: (310) 478-4500 Fax: (310) 478-4546 Email Address: [email protected] Greater San Diego and Desert Area Chapter 7850 Mission Center Ct. Ste. 100 San Diego, CA 92108 Phone: (619) 497-1300 Fax: (619) 497-1304 Email Address: [email protected] Northern California Chapter 5 Third St., Suite 625 San Francisco, CA 94103 Phone: (415) 356-2232 Fax: (415) 356-0880 Email Address: [email protected] COLORADO Rocky Mountain Chapter 1777 South Bellaire Street, Suite 230 Denver, CO 80222-4310 Phone: (303) 639-9163 Fax: (303) 639-9166 Email Address: [email protected] CONNECTICUT Connecticut Chapter P.O. Box 275 Branford, CT 06405 Phone: (203) 208-3130 Email Address: [email protected] FLORIDA Florida Chapter 21301 Powerline Rd., Suite 301 Boca Raton, FL 33433 Phone: (561) 218-2929 Fax: (561) 218-2240 Email Address: [email protected] North Florida Chapter P.O. Box 14959 Jacksonville, FL 32238-4959 Phone: (646) 201-6468 Fax: (904) 738-7216 Email Address: [email protected] GEORGIA Georgia Chapter 2250 North Druid Hills Road, Suite 250 Atlanta, GA 30329-3118 Phone: (404) 982-0616 Fax: (404) 982-0656 Email Address: [email protected] IOWA Iowa Chapter P.O. Box 1944 Council Bluffs, IA 51502 Phone: (847) 827-0404 Email Address: [email protected] ILLINOIS Illinois Carol Fisher Chapter 2200 East Devon Avenue, Suite 351 Des Plaines, IL 60018-4509 Phone: (847) 827-0404 Fax: (847) 827-6563 Email Address: [email protected] INDIANA Indiana Chapter 931 East 86th Street, Suite 210 Indianapolis, IN 46240 Phone: (317) 259-8071 Fax: (317) 259-8091 Email Address: [email protected] KENTUCKY Kentucky Chapter c/o Tennessee Chapter 95 White Bridge Road, Suite 209 Nashville, TN 37205 Phone: (615) 356-0444 Fax: (615) 356-0445 Email Address: [email protected] LOUISIANA Louisiana/Mississippi Chapter 7611 Maple Street, Suite B New Orleans, LA 70118 Phone: (504) 861-3433 Fax: (504) 861-3466 Email Address: [email protected] MASSACHUSETTS New England Chapter 280 Hillside Avenue, Fl. 2, Ste. 9 Needham, MA 02494-1365 Phone: (781) 449-0324 Fax: (781) 449-0325 Email Address: [email protected] MARYLAND Maryland/Southern Delaware Chapter 10400 Little Patuxent Parkway, Suite 270 Columbia, MD 21044 Phone: (443) 276-0861 Fax: (443) 276-0865 Email Address: [email protected]

37
MICHIGAN Michigan Chapter 31313 Northwestern Highway, Suite 204 Farmington Hills, MI 48334-2577 Phone: (248) 737-0900 Fax: (248) 737-0904 Email Address: [email protected] MINNESOTA Minnesota/Dakotas Chapter 1885 University Avenue West, Suite 355 St. Paul, MN 55104-3462 Phone: (651) 917-2424 Fax: (651) 917-2425 Email Address: [email protected] MISSOURI Mid-America Chapter 1034 S. Brentwood Blvd., Suite 1510 St. Louis, MO 63117 Phone: (800) 783-8006 Fax: (314) 863-4749 Email Address: [email protected] NORTH CAROLINA Carolinas Chapter 2901 North Davidson Street, Suite 160 Charlotte, NC 28205 Phone: (704) 332-1611 Fax: (704) 332-1612 Email Address: [email protected] NEBRASKA Nebraska Chapter 1941 South 42nd Street, Suite 543 Omaha, NE 68105-2939 Phone: (402) 505-9901 Fax: (402) 505-9931 Email Address: [email protected] NEW JERSEY New Jersey Chapter 45 Wilson Avenue Manalapan, NJ 07726-1501 Phone: (732) 786-9960 Fax: (732) 786-9964 Email Address: [email protected] NEW YORK Fairfield/Westchester Chapter 200 Bloomingdale Road, 2nd Floor White Plains, NY 10605-1514 Phone: (914) 328-2874 Fax: (914) 328-2946 Email Address: [email protected] Greater New York Chapter 386 Park Avenue South, 14th Floor New York, NY 10016-8804 Phone: (212) 679-1570 Fax: (212) 679-3567 Email Address: [email protected] Long Island Chapter 585 Stewart Avenue, Suite 580 Garden City, NY 11530-4701 Phone: (516) 222-5530 Fax: (516) 222-5535 Email Address: [email protected] Rochester, New York/Southern Tier Chapter 2117 Buffalo Road, Suite 299 Rochester, NY 14624 Phone: (585) 617-4771 Fax: (585) 617-4771 Email Address: [email protected] Upstate/Northeastern New York Chapter 4 Normanskill Blvd. Delmar, NY 12054 Phone: (518) 608-5069 Email Address: [email protected] Western New York Chapter 2714 Sheridan Drive Tonawanda, NY 14150 Phone: (716) 833-2870 Fax: (716) 783-7899 Email Address: [email protected] OHIO Central Ohio Chapter 5008 Pine Creek Drive, Suite A Westerville, OH 43081 Phone: (800) 625-5977 Fax: (614) 865-1934 Email Address: [email protected] Northeast Ohio Chapter 23775 Commerce Park Road Beachwood, OH 44122 Phone: (866) 345-2232 Fax: (216) 831-2792 Email Address: [email protected] Southwest Ohio Chapter 8 Triangle Park Drive, Suite 800 Cincinnati, OH 45246 Phone: (877) 283-7513 Fax: (513) 772-7599 Email Address: [email protected] OKLAHOMA Oklahoma Chapter c/o North Texas Chapter 12801 North Central Expressway, Suite 270 Dallas, TX 75243 Phone: (918) 523-8540 Fax: (972) 386-0509 Email Address: [email protected] PENNSYLVANIA Philadelphia/Delaware Valley Chapter 367 East Street Road Trevose, PA 19053-7711 Phone: (215) 396-9100 Fax: (215) 396-1170 Email Address: [email protected] Western Pennsylvania/West Virginia Chapter 300 Penn Center Boulevard, Suite 401 Pittsburgh, PA 15235 Phone: (877) 823-8272 Fax: (412) 823-8276 Email Address: [email protected] TENNESSEE Tennessee Chapter 95 White Bridge Road, Suite 209 Nashville, TN 37205 Phone: (866) 814-2232 Fax: (615) 356-0445 Email Address: [email protected] TEXAS Houston Gulf Coast/South Texas Chapter 5120 Woodway, Suite 8008 Houston, TX 77056-1758 Phone: (800) 785-2232 Fax: (713) 572-2433 Email Address: [email protected] North Texas Chapter 12801 North Central Expressway, Suite 270 Dallas, TX 75243 Phone: (972) 386-0607 Fax: (972) 386-0509 Email Address: [email protected] VIRGINIA Greater Washington, D.C./Virginia Chapter 4085 Chain Bridge Rd., Suite 201 Fairfax, VA 22030 Phone: (877) 807-5271 Fax: (703) 865-8873 Email Address: [email protected] WASHINGTON Northwest Chapter 9 Lake Bellevue Drive, Ste. 203 Bellevue, WA 98005 Phone: (877) 703-6900 Fax: (425) 451-1708 Email Address: [email protected] WISCONSIN Wisconsin Chapter 1126 S. 70th Street, Suite S210A West Allis, WI 53214 Phone: (877) 586-5588 Fax: (414) 475-5502 Email Address: [email protected]

Our Chapters

Leadership & Staff
OFFICERS Mark Goldman Chair of the National Board Weston, MA Jonathan Braun, M.D., Ph.D. Chair, National Scientific Advisory Committee Los Angeles, CA Gary Sinderbrand Chair-Elect of the National Board Linwood, NJ Bernard Eizen, Esq. General Counsel Philadelphia, PA Louis Plung Treasurer Pittsburgh, PA Richard Kleinman Secretary Syosset, NY IMMEDIATE PAST CHAIR Eugene Kestenbaum Immediate Past Chair of the National Board Huntingdon Valley, PA TRUSTEES David Alberga La Jolla, CA Richard S. Blumberg, M.D. Boston, MA Kenneth Edmonds Silver Spring, MD Arthur Falcone Boca Raton, FL George Ferry, M.D. Houston, TX Lawrence Finkelstein Philadelphia, PA Sanford J. Grossman, Ph.D. Greenwich, CT Michael J. Koss Milwaukee, WI Joel H. Margolese Andover, MA Henry Mordoh Pittsburgh, PA Susan N. Peck, M.S.N., C.R.N.P. Wynnewood, PA David A. Piccoli, M.D. Philadelphia, PA Marysue Wechsler Fairfax, VA

39
CHAIRS EMERITI 1967 to present *Irwin M. Rosenthal, Riverdale, NY ** William D. Modell (deceased) Irving Rubin (deceased) Lynn Meyerhoff (deceased) Stephen Blank, Watchung, NJ Suzanne Rosenthal, Riverdale, NY Jane W. Present, New York, NY Morgan K. Powell, Collinsville, OK Robert A. Brine, Edmonds, WA Scott R. Allswang, Phoenix, AZ Lisa H. Richardson, Houston, TX
*Founding President **Founding Chair

NATIONAL SCIENTIFIC ADVISORY COMMITTEE CHAIRS EMERITI Richard S. Blumberg, M.D. Immediate Past Chairperson Professor of Medicine Chief, Gastroenterology Division Brigham & Women’s Hospital Boston, MA Theodore M. Bayless, M.D. Professor of Medicine, Sherlock Hibbs Professor of IBD Director, Meyerhoff Digestive Disease and IBD Center The Johns Hopkins Medical Institutions Baltimore, MD Charles O. Elson, M.D. Basil I. Hirschowitz Chair in Gastroenterology Professor of Medicine and Microbiology Vice-Chair for Research, Department of Medicine University of Alabama at Birmingham Birmingham, AL Kurt J. Isselbacher, M.D. Massachusetts General Hospital Cancer Center Mallinckrodt Distinguished Professor of Medicine Boston, MA Henry D. Janowitz, M.D. (deceased) Joseph B. Kirsner, M.D., Ph.D. Louis Block Distinguished Service Professor of Medicine The University of Chicago Chicago, IL Burton I. Korelitz, M.D. Chief of Gastroenterology, Emeritus Director of Research in IBD Lenox Hill Hospital Professor of Medicine, NYU School of Medicine New York, NY Richard P. MacDermott, M.D. Thomas Ordway Endowed Chair Albany Medical College Albany, NY R. Balfour Sartor, M.D. Professor of Medicine, Microbiology, and Immunology University of North Carolina at Chapel Hill Chapel Hill, NC

Stephan R. Targan, M.D. Director, Cedars-Sinai Division of Gastroenterology Director, Cedars-Sinai Inflammatory Bowel Disease Center Feintech Family Foundation Chair in Inflammatory Bowel Disease Cedars-Sinai Medical Center Professor, UCLA School of Medicine Los Angeles, CA NSAC COMMITTEE Jonathan Braun, M.D., Ph.D. Chair, NSAC Professor, Geffen School of Medicine UCLA Medical Center Chair, Department of Pathology & Lab Medicine Los Angeles, CA Richard S. Blumberg, M.D. Immediate Past Chairperson Professor of Medicine Chief, Gastroenterology Division Brigham & Women’s Hospital Boston, MA John A. Barnard, M.D. Liaison, North American Society of Pediatric Gastroenterology Hepatology, and Nutrition (NASPGHAN) Professor, Pediatrics Ohio State University Columbus, OH Robert Burakoff, M.D. Chair, Editorial Board Clinical Chief, Division of Gastroenterology Brigham & Women’s Hospital Boston, MA Sean Colgan, Ph.D. Chair, Research Training Awards University of Colorado Health Sciences Center Kern Professor of Medicine Director, Mucosal Inflammation Pgm Denver, CO Victor W. Fazio, M.D. Liaison, Surgical Affairs Colorectal Surgery Department Chair The Cleveland Clinic Cleveland, OH Stephen P. James, M.D. Liaison, National Institutes of Health Director, Division of Digestive Diseases and Nutrition National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda, MA

Leadership & Staff

HONORARY BOARD MEMBERS Co-founders Irwin M. Rosenthal and Suzanne Rosenthal William D. Modell (deceased) and Shelby Modell Henry D. Janowitz, M.D. (deceased) Members Scott R. Allswang, Phoenix, AZ Theodore Bayless, M.D., Baltimore, MD Rolf J. Benirschke, San Diego, CA Stephen Blank, Watchung, NJ Edgar Cullman, Jr., New York, NY Joel Cutler, Boston, MA Theodore and Joan Cutler, Needham, MA Charles O. Elson, M.D., Birmingham, AL Diane Goldman, Weston, MA Kurt J. Isselbacher, M.D., Charlestown, MA Eugene A. Kestenbaum, Huntingdon Valley, PA Joseph B. Kirsner, M.D., Ph.D., Chicago, IL Burton I. Korelitz, M.D., New York, NY Esther Kusher (deceased) Donald and Mary Jo Lenauer, Owensville, MO Richard P. MacDermott, M.D., Albany, NY Jeffrey Mankoff, Dallas, TX Michael McCready, Seattle, WA Trish McEvoy, New York, NY Lynn Meyerhoff (deceased) Mary Ann Mobley and Gary Collins, Beverly Hills, CA Michael Modell (deceased) Peter Nielsen, Commerce, MI Mandy Patinkin, New York, NY Marsha Patinkin (deceased) Donald Pray, Tulsa, OK Lisa Richardson, Houston, TX Irving Rubin (deceased) Judy Saphir (deceased) R. Balfour Sartor, M.D., Chapel Hill, NC Stephan R. Targan, M.D., Los Angeles, CA

Uma Mahadevan-Velayos, M.D. Chair, Patient Education Assistant Clinical Professor of Medicine University of California San Francisco San Francisco, CA Susan N. Peck, R.N. Liaison, Nursing Affairs Children’s Hospital of Philadelphia Division of Gastroenterology Philadelphia, PA John D. Rioux, Ph.D. Chair, DNA/Cell Line Bank Associate Professor of Medicine Montreal Heart Institute Montreal, Quebec David Rubin, M.D. Chair, Professional Education Assistant Professor, Gastroenterology University of Chicago Chicago, IL Bruce E. Sands, M.D., M.P.H. Chair, Clinical Research Alliance Associate Professor of Medicine Harvard Medical School Massachusetts General Hospital Boston, MA Joseph H. Sellin, M.D. Liaison, Professional Affairs Director, C2-CREATE IBD Center Division of Gastroenterology, UTMB Galveston, TX William F. Stenson, M.D. Chair, Research Initiatives Professor of Medicine Washington University Medical Center Division of Gastroenterology St. Louis, MO Francisco Sylvester, M.D. Chair, Pediatric Affairs Assistant Professor, Pediatrics Connecticut Children’s Medical Center Division of Gastroenterology & Nutrition Hartford, CT Stephan R. Targan, M.D. Chair, Grants Council Director, Cedars-Sinai Division of Gastroenterology and IBD Center Professor, UCLA School of Medicine Los Angeles, CA Casey T. Weaver, M.D. Chair, Grants Review Professor of Pathology and Microbiology University of Alabama at Birmingham Birmingham, AL

NATIONAL OFFICE STAFF LEADERSHIP Richard J. Geswell President R. Balfour Sartor, M.D. Chief Medical Advisor Michael J. Galvin, CPA Chief Operating Officer/ Chief Financial Officer Judith Arner Brown Vice President of Chapter Services/ Revenue Generation Kimberly Frederick Vice President of Patient, Professional & Educational Services Marjorie Merrick Vice President of Research & Scientific Programs Marie Granieri Senior Director of Marketing Stacy Parmele Senior Director of Human Resources

Our Vision
A future free from Crohn’s and colitis.

National Office 386 Park Avenue South, 17th Floor New York, NY 10016-8804 800.932.2423 212.685.3440 Web site: www.ccfa.org E-mail: [email protected]